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Abstract 
 
 Natural products have, historically, played an important role in drug discovery. 
Nevertheless, drug resistance, pathogen evolution, and global climate change threaten 
human health and nearly all current anti-infective treatments on the market today. It is 
undeniable that new drug discovery efforts are needed with increasing urgency.  
 Bolstered by a rich history of discovering treatments in the world around us, 
natural products chemists continue to look to the environment with increasing 
understanding and emerging technologies that allow efficient, effective isolation of new 
chemical entities. This thesis will describe one such endeavor. 
 Focusing on fungal natural products, herein is described the isolation and 
structure elucidation of new, bioactive natural products. Further, the development and 
implementation of a large fungal screening program will be discussed, the results of 
which stand to advance microbial drug discovery in the Baker lab for years to come.  
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Chapter 1. 
An Introduction to Marine Natural Product Drug Discovery 
 
1.1. Why Natural Products 
 From single celled protozoa to homo sapiens, all living beings are comprised of organic 
molecules that make up the cellular machinery essential for life. While some of these compounds 
must be acquired from the organisms’ surroundings, many of these metabolites that are necessary 
for basic cellular function are produced de novo by the cell. These primary metabolites- sugars, 
proteins, lipids, etc. may vary significantly form one life form to another, but the basic chemical 
composition of each living thing is the same. While DNA structure and composition surely 
separates a bacterium from a human being, an investigation of the chemicals found within a 
single cell from either of those organisms will expose a high level of similarity in the 
aforementioned primary metabolites. What may differ chemically within this investigation, 
however, is the myriad of small molecules seemingly unnecessary to primary cellular function. 
These “secondary metabolites”, or natural products, are generally signaling molecules that allow 
the organism not only to survive, but to thrive. All of these metabolites- primary and secondary- 
allow living organisms to live amongst and interact with one another. At a purely chemical level, 
all of life is competing on the same playing field, and this is the basis for interactions between 
species.  
 Given that all life forms have the potential to interact with each other chemically- one 
organism produces a molecule that interacts with a receptor in another organism- it therefore 
2 
  
follows that the study of these natural products can be of great benefit to human health. For, what 
is human disease but an interaction between life forms? What is a drug, but a molecule that 
interacts with a receptor?  
 With advances in technologies that allow us to visit and sample from all corners of the 
globe, we now understand that there is immeasurable biological and chemical diversity just 
waiting to be discovered. This chemical diversity is an incredible source for drug discovery. The 
creativity of the human mind is nothing compared to the creativity of evolution, and we continue 
to discover natural products with novel chemical scaffolds never before seen or imagined 
through synthetic methods. Further, natural products have consistently played a strong role in the 
development of new drugs for human health, with a full 65% of all small molecule approved 
drugs since 1981 being inspired by, derivatives of, or directly, natural products.1   
 While the natural products of terrestrial communities have long been studied for their 
applications to human health,1–4 marine environments have added their own repertoire of 
important compounds to the list over the past few decades.1,5–8 With relatively newly accessible 
regions of the marine environment (namely, deep water and polar communities)9–11 the 
biological and chemical diversity of marine environments poses great potential for 
bioprospecting.  
 
1.2.  Sources of Marine Natural Products 
 1.2.1. Marine Macro-organisms 
 The world’s oceans cover more than 70% of the planet. The exceptionally varied 
environments within these oceans range around the globe from the tropics to the poles. Even in 
the harshest of these environments, intense biodiversity can be found. Within these biodiversity 
3 
  
hotspots, marine organisms have adapted unique physical and chemical attributes to support their 
survival and proliferation. Benthic marine macro-organisms- multicellular organisms, 
specifically those that are sedentary and lack any physical defense mechanisms- have been of 
interest for their chemistry for some time, both in the chemical ecology and drug discovery 
arenas12–15.  
Many new and novel pharmacophores have been discovered from organisms on the 
marine benthos,1,5 and currently, there are two such compounds that are commercially available 
as drugs: ziconotide (Prialt®) from the marine cone snail Conus magnus8, and trabectedin 
(Yondelis®) isolated from the tunicate Ecteinascidia turbinate6,7. Countless other marine natural 
products that have not yet made it through the drug development pipeline exhibit early and 
exciting activities in various bioassays5,12,13,16, inspiring future marine natural products discovery 
efforts.  
1.2.2. Marine Micro-organisms 
While marine macro-organisms have been found to contain interesting secondary 
metabolites,1,5 efforts towards any drug development with these compounds are often met with 
the issue of supply. Many benthic marine organisms cannot be cultured in an artificial setting17 
and are often originally collected in some of the most remote and difficult to access regions of 
the world. Harvesting the biomass of these organisms needed for complete drug development 
would be impossible without great ecological impact. Though they could present a source-
independent supply, synthetic routes to some of these complex scaffolds remain extremely 
difficult.18 Therefore, attaining an adequate supply of marine macro-organism derived 
compounds of interest for the rigorous drug development pipeline can be an extremely daunting 
challenge.  
4 
  
In fact, faced with this problem, and utilizing advances in genetic sequencing and 
microbial isolation techniques, it has been discovered that many natural products initially 
isolated from marine macro-organisms actually originate from invertebrate associated micro-
organisms.5,13  With attention turning towards the density, diversity, and biosynthetic capabilities 
of marine microorganisms, the collection, isolation, and culture of these important and 
sometimes elusive marine participants has become an interesting area of study.13,19–21  
1.2.3. Marine Plant Endophytes 
The discovery of the potent anti-cancer drug paclitaxel (taxol®) from the yew tree, Taxus 
brevifolia, added to the already successful narrative of terrestrial plant natural products as an 
important source of bioactive compounds.22 However, everything changed after paclitaxel was 
later isolated from the endophytic fungus Taxomyces andreanae.23 The study of endophytic 
micro-organisms, specifically endophytic fungi, was elevated significantly, and today, 
endophytic fungi are considered an important source of natural products.24–26  
In the marine realm, mangrove plants have emerged as a significant source of endophytic 
fungi. Found in the harsh fringe marine environments across the globe, mangrove forests are well 
known for intense biodiversity, as well as their adaptations to withstand consistently changing 
temperature and salinity. Endophytic fungi isolated from these environments have been of 
particular interest,26–29 but interestingly, none of the work reported included the mangrove 
environments in Florida, USA. After a number of collections in Everglades National Park and 
other mangrove communities in Florida, a proof of concept study by Beau et al. demonstrated 
that, unsurprisingly, these local mangrove environments were an untouched resource of 
endophyte biological and chemical diversity.30 The work described herein in chapters 3 and 4 
5 
  
seeks to build on these initial studies, hopefully adding to the case for further investigation, 
appreciation, and protection of these exciting marine environments. 
1.2.4. Collection Locations and Non-marine Sources  
Perhaps as important as choosing a target organism is choosing a collection location. The 
marine environment is a vast and variable biome, and much of it still remains to be explored. 
Even the most well studied marine environments- the tropics, for example, with their easily 
accessible reef systems and temperate climates- are changing and evolving with climate change 
and anthropomorphic stressors. With these changes, come changes in the diversity of life and 
chemistry that can be found there. The same can be said for terrestrial and fresh water 
environments, and as scientific tools and instrumentation become more advanced the study of 
natural products from all corners of the globe remains an exciting adventure.  
  1.2.4.1. Antarctica. Niche environments in the low to middle latitude seas of the 
world are extremely interesting, for here, currents make possible the diverging and converging of 
species across the globe. This means, in some instances, that species may have an extremely 
large distribution and remain relatively similar. Antarctica, however, is an example of an 
environment in which this is not true. Upon the splitting of the continent from Australia and 
South America some 30 million years ago, the Antarctic Circumpolar current was formed, 
effectively cutting the continent and its surrounding waters off from the rest of the globe. These 
freezing, isolated waters are now home to organisms that have evolved through periods of 
fluctuating glaciation and without influence from the currents and winds from the tropics. Those 
organisms living on the benthos in this environment- both macro-organisms and their micro-
organism compatriots- have evolved many chemical interactions with one another as a way to 
survive. These species often exhibit rich biosynthetic potential, and the study of secondary 
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metabolites produced in this environment is of great interest to many groups- including ours.9,31–
33  
The Baker lab Antarctic collection features organisms collected by SCUBA and trawling 
in the areas of Palmer Station and throughout the Scotia Arc (Figure 1.1) over decades of visits 
to the continent. 
 
Figure 1.1. The Antarctic continent as seen from space on Google Earth with common collection 
sites for natural products featured. (Image credit: J. L. Fries)34   
 
In the winter of 2016-17, we participated in the Swiss Polar Institute’s Antarctic 
Circumnavigation Expedition (ACE), sampling, in some places for the first time, via Agassiz 
trawl, ROV, and intertidal collections throughout the sub-Antarctic waters and islands (Figure 
1.2).  
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Figure 1.2. The Swiss Polar Institute’s ACE cruise plan, December 2016- March 2017. (Image 
Credit: Swiss Polar Institute) 
 
Samples collected during this expedition include bulk material for chemical investigation as well 
as tissue samples preserved for the isolation of associated fungi and bacteria. All macro-
organisms collected will be genetically identified at the Western Australia Museum by Dr. 
Nerida Wilson. Illustrating an ideal example of an understudied and interesting niche 
environment, our Antarctic investigations are bolstered by strong collaborations that help to 
advance our studies of this wildest of marine frontiers. 
  1.2.4.2. Florida. Though we travel to the ends of the earth to collect samples, the 
Baker lab calls the University of South Florida, in Tampa, Florida, home. Fortunately, Florida is 
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home to a number of unique marine environments that are also ideal collection locations for the 
isolation of natural products. Florida supports vast mangrove forests in both developed and 
protected areas (Figure 1.3). These mangrove communities, as mentioned above, are rather 
understudied, and are ideal for the collection of endophytic fungi and bacteria.  
 
 
Figure 1.3. Left panel: Mangroves growing in highly developed intercoastal waterways in 
Dunedin, FL; Right panel: Mangroves growing in the protected, pristine Everglades National 
Park, FL. 
 
Florida’s warm waters also support beautiful coral reef communities in the Keys and up the west 
coast into the Gulf of Mexico. With just a short boat ride, SCUBA divers from the lab can collect 
a vast array of benthic organisms for chemical and microbial investigation. Convenience is not to 
be taken for granted in the choosing of a site from which to collect material for natural products 
research, and sometimes you only have to look as far as your own back yard.  
  1.2.4.3. Terrestrial and fresh water environments. Nowhere is this mantra better 
proven than in chapter 2 of this manuscript. Sedentary and microbial organisms in all 
environments- marine, terrestrial, and fresh water- must produce secondary metabolites with 
which they can interact with the world around them. Micro-environments, such as fresh water 
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ponds, inner-city forests, or coastal estuaries, to name a few, may be home to countless 
organisms that must respond to incredibly localized stressors that make no two environments 
exactly the same. Chapter 2 will tell the fortuitous story of noticing a new organism (a fresh 
water bryozoan) growing in a neighborhood retention pond that resulted in the isolation of a suite 
of new, bioactive compounds.  
 Natural products exist all around us, and nature is the supreme synthetic chemist. Even 
our own human gut microbiome is currently demanding attention for secondary metabolite 
production and the potential for therapeutic applications.35–37 New chemical structures are 
emerging all the time from countless environmental sources, and as threats to human health 
evolve, it could certainly be argued that natural products research is the way forwards.  
 
1.3.  Approaches Towards the Isolation of Microbial Natural Products 
 1.3.1. Collection and Isolation 
 The majority of marine microbes are still considered “unculturable”, however, much 
work has gone into shrinking that percentage by investigating new collection, isolation, and 
culture techniques.20,26,38 The fungal library in the Baker lab at the University of South Florida 
serves as a comprehensive example of microbial isolates obtained using an evolving repertoire of 
techniques from a variety of sources. Marine organisms such as sponges, tunicates, and corals 
are collected either by SCUBA or trawling, and small tissue samples are surface sterilized before 
being plated on a variety of solid media plates featuring varying chemical and nutrient 
compositions. Mangrove and mangrove-associated plant material is similarly collected and 
inoculated. Sediment and water column samples are concentrated, or filtered, before being plated 
on solid media or suspended in liquid media. Collection and isolation techniques are adaptable to 
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the source organism or targeted isolates. Microbial isolate cultures can be miniaturized and 
standardized, as will be discussed in chapter 3, for screening purposes, or scaled up and tailored 
for titer improvement of compounds of interest.30 By keeping a functional archive of all isolates 
(stored at -80°F) this microbial library can be investigated again and again as new culture 
techniques and screening targets emerge.  
 1.3.2. Culture Techniques 
 Thanks to genomic advancements, it is clear that micro-organisms cultured in the lab 
routinely produce only a fraction of the secondary metabolites that are coded for in their DNA.39 
This is accomplished by the regulation of transcription by enzymes activated and deactivated 
based on environmental factors.40 In filamentous fungi, we know that most secondary metabolite 
genes are clustered to allow for the most efficient regulation,40,41 and these clusters can be 
activated or deactivated by culture conditions, resulting in vastly different metabolite production. 
Once isolated, a micro-organism of interest can be cultured in the lab under any number of easily 
accessible stressors that can change secondary metabolite production. Culture variations can be 
as simple as changing the shape of the culture vessel, or as complex as the addition of biological 
material from another microbe or host organism. In this way, a single strain can produce a 
multitude of different compounds.39,42–45 While this ‘OSMAC’ (‘One Strain Many 
Compounds’)44 strategy is extremely useful in exploiting the full biosynthetic potential of a 
micro-organism of interest, it is rather intensive in time and consumables.  
 Rather than systematically changing culture conditions, the biosynthetic potential of a 
micro-organism of interest can also be explored through whole genome sequencing. Many 
secondary metabolites are products of known biosynthetic pathways. The ability to ascribe a 
product to the genes that code for it allows for the unique ability to analyze a whole genome and 
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predict the metabolites that can be produced. Culture conditions curated to that biosynthetic 
pathway can then be employed to isolate specific compounds of interest.46–51  
 Genome mining and the OSMAC approach are both useful techniques for the discovery 
of the biosynthetic potential of a single organism. If, however, you have a microbial library that 
you would like to screen, these techniques may not be the most efficient. Epigenetic 
modification- that is, the use of small molecule enzyme inhibitors to promote the expression and 
prevent the silencing or downregulation of secondary metabolite gene clusters52–55- can be used 
as a more ubiquitous technique to exploit the biosynthetic potential of a larger number of micro-
organisms. Chapter 3 will discuss the use of histone deacetylase (HDAC) and DNA 
methyltransferase (DNMT) inhibitors30 as culture additives to epigenetically ‘turn on’ secondary 
metabolite gene clusters in a library of filamentous fungi for the maximum surveying of 
bioactive natural product potential therein.  
 
1.4.  Drug Discovery Targets  
 Natural products isolation efforts largely follow the same generic scheme (Scheme 1). 
Efforts aimed at drug discovery can take place at any of the stages, from extraction to pure 
compound isolation. There are pros and cons to each approach, though it is generally accepted 
that the earlier you can prioritize your efforts, the better.   
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Scheme 1.1. A generic flow chart for natural product isolation.  
 
Crude extracts can contain thousands of compounds, however, it is possible to get useful 
information from that complex mixture in a high-throughput way. Metabolite profiling of crude 
extracts can be used for initial dereplication and more advanced matabolomic analysis can reveal 
chemical outliers that may be of interest.56,57 High-throughput bioassays that are tolerant of 
complex mixtures can be used to discover and prioritize activity early in the investigation 
process. More sensitive and selective bioassays that are not tolerant of complex mixtures would 
require more purified fractions or pure compounds. It is important, therefore, when embarking on 
a natural products screening program, to coordinate bioassay capabilities to isolation protocols, 
in addition to other target selection criteria. The descriptions that follow comprise the panel of 
targets that will be discussed in Chapter 3. These targets are of great contemporary relevance to 
Crude 
Extract
Liquid/Liquid 
Partition
Liquid/Liquid 
Partition
Fraction Fraction
Fraction Fraction
Purified 
Fraction
Purified 
Fraction
Purified 
fraction
Pure 
compound
13 
  
human health concerns and each feature robust bioassay methodologies that assist in early crude 
extract level prioritization.  
1.4.1. The ESKAPE Pathogens  
With growing antibiotic resistance, and a decrease in antibiotic drug discovery, the 
Infectious Disease Society of America issued a ‘call to arms’ in 2009 to the drug discovery 
community to combat what they called the ESKAPE pathogens: the gram positive Enterococcus 
faecium and Staphylococcus aureus, and gram negative Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae.58 These clinically relevant, 
highly drug resistant pathogens represent a continuously growing threat to human health and an 
important target for drug discovery efforts.59,60  
1.4.2. Leishmania donovani 
A neglected tropical disease (NTD), Leishmaniasis is a parasitic infection caused by an 
intramacrophage protozoa that is transmitted to humans by the bite of infected sandflies. The 
visceral form of this disease, most commonly caused by Leishmania donovani, is typically fatal 
when left untreated. Upon entering the host, the parasite –in a non-flagellated amastigote life 
stage- invades macrophage cells to travel through the body and reproduce.61 Recent advances in 
infected macrophage in-vitro culture techniques allow for more clinically relevant assays to be 
performed in a high throughput screening (HTS) context.62–64 These advancements will hopefully 
aid in the discovery of new treatments for this disease in the face of increasing resistance to 
existing treatments.65  
 1.4.3. Mycobacterium tuberculosis 
 Tuberculosis (TB) remains a global health crisis, despite the advances of the whole 
genome sequencing project that revealed the genome of Mycobacterium tuberculosis. This 
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disease, whose latent form is estimated to infect one third of the world’s population, poses many 
drug development hurdles. Multi-drug resistant (MDR-TB) and extensively drug resistant (XDR-
TB) strains have emerged despite the current course of treatment typically involving 
combinatorial therapies aimed directly at preventing resistance. Drug discovery efforts, 
therefore, must address new mechanisms of action or M. tuberculosis targets. Additionally, TB 
drugs have the burden of needing to be compatible in combinatorial treatments for the 
immunocompromised, particularly those with HIV/AIDS, among whom incidence of this disease 
are highest.66 Natural products based drug discovery against this target have revealed promising 
results, with many existing treatments coming from natural products. With such a demanding 
target comes the need to screen a broad swath of chemical space, confirming natural products 
drug discovery efforts as a promising way forward in the search for treatments of this disease.67  
 1.4.4. Clostridium difficile 
 The leading cause of healthcare related infection, Clostridium difficile is an easily spread, 
diarrhea causing bacteria that is considered a threat to human health worldwide. The use of 
antibiotics which upset the human gut microbiome is the primary cause of C. difficile infection 
(CDI), but any immunocompromised individuals are at risk. With increasing incidences of 
resistance, recurrence, and mortality, the need for discovery of new treatments against this 
bacteria is imperative. Most challengingly, new drugs to fight CDI must act without impact on 
the normal human gut fauna. Many novel treatment avenues have been suggested, among which, 
the discovery and use of bacterial natural products remain of high interest.68–70   
 1.4.5. Naegleria fowleri 
Naegleria fowleri is a free living, warm-water loving amoeba that causes the nearly 
always fatal primary amoebic meningoencephalitis (PAM). Diagnosis of PAM is extremely 
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difficult, and current treatment options are time sensitive and limited to existing drug 
combinations (e.g. Amphotericin B, fluconazole, and miltefosine).71,72 As clinicians start to 
understand and diagnose PAM better, and the risk of this disease continues to rise with 
increasing global temperatures, new drugs that specifically target this amoeba are urgently 
needed.  
 1.4.6. Cancer Targets 
 With structures as diverse as their targets, natural products have long played a role in the 
treatment of various cancers.1,22,73 As understanding of the complex physiology of human cells 
(both healthy and cancerous) continues to grow, assays directed at testing compounds against 
highly specific cellular targets continue to emerge. Rather than whole cancer-cell assays, these 
target specific assays can help to exclude compounds that are broadly cytotoxic to all cells in 
favor of compounds that are active within the specific mechanism of action that is desired.  
 Autopalmitoylation dysregulation is implicated in many disease states. In a newly 
developed assay, palmitoylation of proteins can be monitored for modulation by compounds of 
interest in a HTS manner. This allows compounds to be rapidly screened not for their effect on 
the whole cell, but rather just on this particular pathway of interest.74  
 
1.5. Future Directions  
 As I have attempted to illustrate, there are many different techniques available for natural 
products drug discovery efforts. While exploring the biosynthetic potential of a single organism 
can be very lucrative, screening efforts are needed in order to identify those “lead” organisms. 
With a robustly designed screening program, natural product extracts from a multitude of sources 
can be screened side by side in high-throughput capable bioassays against a wide variety of 
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disease targets. The resulting diversity of bioactivity information combined with metabolite 
profiling can afford intense prioritization of extracts at a very early stage (Scheme 1.1), 
streamlining further chemical investigation to a highly time and cost effective level of efficiency. 
Focusing on marine fungi, the remaining chapters in this dissertation will put forth evidence in 
support of one such screening initiative, its successes, lessons, and some recommendations for 
improvements moving forward. The work discussed herein will present a number of new, 
bioactive microbial natural products that resulted from this initiative. At the conclusion, I hope to 
convince the reader that microbial natural products drug discovery can be an efficient, cost 
effective endeavor towards combating some of the most difficult challenges facing human health 
today.  
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Chapter 2 
New Bioactive Meroterpenes from Phomopsis sp. 
 
2.1. BB11-2 Isolation 
In the winter of 2011 small colonies of the fresh water bryozoan Pectinatella magnifica 
were noticed on a morning run in a retention pond located in north Tampa, Florida. These 
colonial organisms were collected for chemical analysis. While collecting, one of the colonies 
was found to be growing around the end of a tree branch that was partially submerged in the 
water. A small piece of this branch was collected along with the bryozoan and returned to the lab 
for processing. Once in the lab, the branch was processed for microbial isolation (procedure in 
Appendix B). From two SDA plates, 7 fungal isolates were obtained based on morphological 
features. These organisms were given a name of “BB11” for “Baker’s Backyard 2011” and 
archived as described in Appendix B.  
Following chemical investigation of isolate BB11-2, fungal identification was obtained 
via Sanger sequencing of the 18S ribosomal spacer region (Appendix A). An NCBI nucleotide 
blast returned identification as Diaporthe or Phomopsis sp.; genera that have been determined to 
be the same but represent different life cycles of these common,1 chemically rich2–7 endophytic 
fungi. For purposes of this dissertation, the isolate will be referred to as Phomopsis sp. 
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2.2.  Initial Bioactivities and Scale-up  
The BB11 fungal isolates were screened in a number of assays and assay development 
protocols and their extracts were known within the lab to be highly active with low cytotoxicity. 
Isolate BB11-2 was chosen for its reproducible bioactivity and tolerance towards multiple media 
types.  As a part of a scale-up optimization study, BB11-2 was scaled up on rice media in three 
growth conditions: control (700g of rice media + 100mL SDB), HDACi (700g of rice media + a 
435µM solution of sodium butyrate in 100mL SDB), and DNMTi (700g of rice media + a 
435µM solution of 5-azacytidine in 100mL SDB). After 21 days of growth, each extract was 
extracted in 1:3 MeOH/ EtOAc solution overnight, followed by 2 subsequent 24 hour extractions 
in 100% EtOAc. The extracts for each of the three culture conditions were dried down and 
subjected to a H2O: EtOAc partition. The lipophilic partitions were each separated on NP MPLC 
(Scheme 2.1). The fractions of the control extract were further investigated.  
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Scheme 2.1. Extraction scheme for Phomopsis sp. Control. 
 
2.3.  Compound Isolation and Structure Elucidation 
 The extract of the control culture condition of Phomopsis sp. was investigated by NMR 
and bioactivity guided fractionation (Scheme 2.1) and yielded 5 new meroterpenes: 
phomopsichromins A-E (1-5), and the known compound LL-Z1272ε (6)8 (Figure 2.1).  
 
 
Phomopsis sp. Control  
Crude Extract 
50g 
H2O partition 
25g 
EtOAc partition 
25g 
NP MPLC: (Hexanes  Ethyl Acetate  Methanol) 
A B C D E F G H 
NP MPLC: (Hexanes  Ethyl Acetate) 
A B D E F C 
Compounds 1-6 
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4 
 
 
 
5 
 
 
 
6 
Figure 2.1. Chemical structures of new compounds 1-5 and known compound 6. 
 
In the first MPLC separation of the lipophilic partition of the Control extract, the majority of the 
mass eluted in one large peak in approximately 1:1 n-hexanes: ethyl acetate. This fraction 
(Fraction D) was further purified via NP MPLC on an extended non-polar gradient (n-hexanes to 
ethyl acetate). Again, the majority of the mass eluted in a single peak in approximately 1:1 n-
hexanes: ethyl acetate (Fraction C). Further purification was accomplished on NP HPLC using a 
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cyano column (CN capping of the silica particles) and UV detection. Compounds 1-6 (Figure 
2.1) were isolated as illustrated in Figure 2.2.   
 
 
Figure 2.2. NP HPLC chromatogram of fraction D_C (Scheme 2.1) from the control growth 
treatment of Phomopsis sp. Peaks are annotated with their isolated compounds (Figure 2.1). Each 
compound required some further purification on reverse phase (RP) HPLC for structure 
elucidation and bioassay purposes, but represented the major component of each of the peaks 
seen. Black is the UV chromatogram at 320nm, and blue is the ELSD trace.  
 
Compounds 1- 6 all share a sesquiterpene backbone functionalized differentially at C-9. 1- 3 
share a chromene substructure while compounds 4- 6 feature a ring-opened subunit. The 
3 
1 
2 
4 
5 
6 
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structures of Phomopsichromins A-E (1- 5) were elucidated as described below. NMR spectra, 
IR, UV, and optical rotation data for all compounds can be found in Appendix A. 
 
Table 2.1. 1D and 2D data for phomopsichromin A (1) in CDCl3.  
Pos δCb δH (m, J(Hz))a HMBCc 
1 50.4 2.41 (q, 6.6 x 2, 1 H) 2, 5, 6, 7, 12, 14 
2 213.8   
3 41.5 2.33 (m, 1 H) 2, 4, 5 
  2.36 (m, 1 H)  
4 30.8 1.64 (m, 1 H) 3, 5, 6, 13 
  1.85 (m, 1 H) 2, 3, 5, 6 
5 36.1 1.97 (m, 1 H) 1, 3, 4, 6, 13 
6 43.2   
7 30.6 1.41 (m, 1 H) 1, 5, 6, 8, 14 
  1.48 (m, 1 H) 1, 5, 6, 8, 14 
8 34.3 1.52 (m, 1 H) 7, 9, 10 
  1.77 (m, 1 H) 7, 15, 9, 10 
9 79.89   
10 125.8 5.46 (d, 10.2, 1 H) 8, 9, 15, 16, 21 
11 116.9 6.76 (d, 10.2, 1 H) 9, 15, 16, 17, 21 
12 7.5 0.91 (d, 6.8, 3 H) 1, 2, 6 
13 14.9 0.89 (d, 6.8, 3 H) 4, 5, 6 
14 15.4 0.59 (s, 3 H) 1, 5, 6, 7 
15 27 1.44 (s, 3 H) 8, 9, 10, 11 
16 106.8   
17 160.6   
-OH  11.74 (s, 1 H) 16, 17, 18, 21 
18 103.6   
19 144.4   
20 111.9 6.24 (s, 1 H) 10, 11, 16, 18, 21, 22, 23 
21 158.6   
22 24 2.55 (s, 3 H) 17, 18, 19, 20, 21, 23 
23 175.1   
a 1H NMR recorded at 500 MHz, reported in ppm (multiplicity, J-coupling in Hz, integration); b 
13C NMR recorded at 125 MHz; c recorded from a gHMBCAD experiment at 500 MHz and 
reported as positions of carbons.   
 
 Phomopsichromin A (1), [α]20D +1.2, was isolated as a white powder. The 1H NMR 
spectrum of 1 (Table 2.1) notably displayed 3 olefinic protons, peaks for 5 methyl substituents, 
and a phenol. The 13C NMR spectrum indicated the presence of a carboxylic acid (δC 175.18) 
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and ketone (δC 213.87). Remaining 13C signals were split between the aromatic and alkene 
regions and implied a high level of substitution on the aromatic ring (as evidenced by the small 
number of olefinic protons in the 1H NMR spectrum). The chromene substructure was tentatively 
assigned based on 2D NMR experiments and 13C ppm shifts of carbons 9 and 21. The remaining 
terpene scaffold was completed based on HMBC and COSY NMR data (Figure 2.3). HRESIMS 
of 1 (m/z 387.2137 [M + H]+) resembled compounds in the literature8–12 but did not match any 
exactly, confirming that 1 was a new compound. Using the NMR data from these related 
compounds, the chromene substructure was confirmed. Relative stereochemical assignments at 
methyl-bearing carbons 1 (R), 5 (R), 6 (S), and 9 (S) were assigned via 1 and 2D NOE 
experiments (Figure 2.3) and comparison to the literature11–13. ECD will be used to confirm 
absolute stereochemistry.  
 
 
Figure 2.3. Important COSY, HMBC, and NOE correlations in phomopsichromin A (1).  
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Table 2.2. 1D and 2D data for phomopsichromin B (2) in CDCl3.  
Pos δCb δH (m, J(Hz))a HMBCc 
1 39.4 1.43 (m, 1H) 2, 6, 12, 14 
2 73.1 3.85 (q, 2.8, 1 H) 3, 4, 6, 12 
3 33.9 1.55 (m, 1 H) 1, 5 
  1.8 (m, 1 H) 1, 2, 4, 5 
4 25.4 1.27 (m, 1 H)  
  1.63 (m, 1 H) 3, 5 
5 36.5 1.46 (m, 1 H) 6, 7, 14 
6 38.2   
7 30.9 1.35 (m, 2 H) 5, 6, 8, 14 
8 34.4 1.45 (m, 1 H) 6, 7, 9 
  1.63 (m, 1 H) 6, 7, 9, 10, 15 
9 80.1   
10 126.2 5.46 (d, 10.2, 1 H) 8, 9, 15, 16 
11 116.6 6.74 (d, 10.2, 1 H) 9, 16, 17, 21 
12 12.3 0.95 (d, 7.1, 3 H) 1, 2, 6 
13 15.6 0.82 (d, 6.6, 3 H) 4, 5, 6 
14 17.3 0.86 (s, 3 H) 7, 6, 5 
15 27.1 1.41 (s, 3 H) 8, 9, 10 
16 106.9   
17 160.6   
-OH  11.80 (s, 1 H) 16, 17, 18 
18 103.4   
19 144.1   
20 111.9 6.22 (s, 1 H) 16, 18, 21, 22 
21 158.7   
22 24.4 2.53 (s, 3 H) 18, 19, 20 
23 174.7   
a 1H NMR recorded at 600 MHz, reported in ppm (multiplicity, J-coupling in Hz, integration); b 
13C NMR recorded at 125 MHz; c recorded from a gHMBCAD experiment at 500 MHz and 
reported as positions of carbons.   
 
 Phomopsichromin B (2) was isolated as a white powder, C23H32O5, HRESIMS m/z 
389.2322 [M + H]+ (calculated, 389.2283),  [α]20D -1.5. Comparison to the HRMS of 1 indicated 
a difference of 2 protons. The appearance of a broad multiplet at δH 3.85 and the loss of the 
ketone signal at δC 213.87 inferred a reduction at C-2. The 2D NMR spectra further supported 
this assignment (Figure 2.4). The stereochemistry at position 2 was determined to be S based on 
the multiplicity observed in the proton NMR spectrum. The observed J-values of the quartet at 
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δH 3.85 most closely matched those expected from the axial orientation of the hydroxyl group. 
This orientation could also be observed in other related compounds in the literature.14 The 
remaining chiral centers were determined to be the same as in 1. Again, the stereochemistry will 
be confirmed via ECD. 
 
 
Figure 2.4. Important COSY, HMBC, and NOE correlations in phomopsichromin B (2). 
 
 Curiously, in multiple 1D NMR analyses of 2 over time, notable shifts in ppm were 
observed for some peaks (e.g. δH 6.22, 3.85, and 2.53; δC 73.17, 103.46, 158.73, and 174.72). 
The assumption was made that there were diastereoisomers present (further supported by some 
poorly resolved crystal data), however, various NP and RP HPLC attempts eluted a single peak 
in all conditions. The beginning, middle, and end of the peak were collected as separate fractions 
(a, b, and c) in an attempt to separate the diastereoisomers.  Clear ppm differences were observed 
between fractions a and c, but they were chromatographically indistinguishable. The decision 
was made to methylate the carboxylic acid at C-23 in fractions a and c to reduce the effects of 
hydrogen bonding in separation attempts and aid in NMR spectral evaluation (Figure 2.5).  
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Figure 2.5. Methylation reaction of 2 (stereochemistry unknown at the time) to yield 7 with 
diazomethane. 
 
The resulting methyl derivatives of fractions a and c (7) were confirmed by 1D NMR (Appendix 
A). All ppm differences between fractions a and c were lost, indicating that all previously noted 
shifts in ppm had been a concentration-based artifact of hydrogen bonding of 2 to itself in 
solution. 2 was determined to be a single diastereoisomer and remaining chemical and biological 
analyses were completed (Appendix A).  
 Phomopsichromin C (3) was isolated as a white powder, [α]20D +1.3. 1H NMR data 
resembled 1 and 2 in the chromene region, however, the methyl signals at position 12, 13, and 14 
were notably shifted downfield and were all overlapping (Table 2.3). New peaks at δC 170.87 
and 21.4, with a new methyl signal in the 1H spectrum (δH 2.05) indicated added ester 
functionalization in the molecule. HRESIMS m/z 431.2434 [M + H]+ (calculated, 431.2389) gave 
a molecular formula of C25H34O6, confirming the addition of a –CO(O)CH3 group. The available 
2D NMR data confirmed that the new functionalization was at C-2 (δC 75.16) (Figure 2.6).  
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Table 2.3. 1D and 2D data for phomopsichromin C (3) in CDCl3.  
Pos δCb δH (m, J(Hz))a HMBCc 
1 38.5 1.55 (m, 1 H) 6, 12, 14 
2 75.1 4.97 (q, 2.0, 1 H) 1 
3 30.9 1.5 (m, 1 H) 1, 2, 4, 5 
  1.81 (m, 1 H)  
4 25.8 1.29 (m, 1 H) 2, 3, 5, 6, 13 
  1.5 (m, 1 H)  
5 36.2 1.47 (m, 1 H) 3, 4, 6, 14 
6 38.3   
7 30.7 1.4 (m, 2H) 1, 5, 8, 9, 14 
8 34.4 1.4 (m, 1H) 7, 9, 10, 11, 15 
  1.65 (m, 1 H)  
9 80.1   
10 126.1 5.45 (d,10.2, 1 H) 8, 9, 15, 16, 21 
11 116.7 6.74 (d, 10.0, 1 H) 9, 15-17, 21 
12 12.0 0.83 (m, 3 H) 2 
13 15.6 0.83 (m, 3 H) 4 
14 16.7 0.83 (m, 3 H) 1, 5, 7, 8 
15 27.1 1.4 (s, 3 H) 8-11 
16 106.8   
17 160.6   
-OH  11.82 (s, 1 H) 16, 17, 18, 21 
18 103.3   
19 144.1   
20 111.9 6.22 (s, 1 H) 11, 16-18, 21-23 
21 158.7   
22 24.4 2.53 (s, 3 H) 16-20, 23 
23 174.4   
24 170.8   
25 21.4 2.05 (s, 3 H) 2, 24 
a 1H NMR recorded at 600 MHz, reported in ppm (multiplicity, J-coupling in Hz, integration); b 
13C NMR recorded at 125 MHz; c recorded from a gHMBCAD experiment at 500 MHz and 
reported as positions of carbons.   
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Figure 2.6. Important COSY and HMBC correlations in phomopsichromin C (3). 
 
Due to the overlapping signals of the methyl signals on the cyclohexane ring of 3, elucidating the 
stereochemistry at C-1, 2, 5, and 6 based on NMR data posed a significant challenge. The methyl 
group at C-9 was assumed, as in compounds 1 and 2, to be S based on chemical shift. The 
stereochemistry at C-2 was again determined to be S based on the 1D 1H multiplicity. Figure 2.7 
illustrates the proposed biosynthetic pathway for the cyclohexane substructure of 1-5 based on 
work done by Tanabe and Suzuki in 1974 on a related compound.13 This pathway indicates that 
the ketone at C-2 is a part of the precursor molecule, and therefore all reductions at C-2 occur 
post translationally. This suggests a conserved chirality at the centers at C-1, C-5, and C-6.  
 
 
Figure 2.7. Proposed biosynthetic pathway towards the cyclohexane substructure of 1-6 from 
Tanabe and Suzuki, 1974.  
 
Based on these assumptions, a compound with proposed stereochemistry (Figure 2.8) was 
submitted for ECD. 
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Figure 2.8. Proposed stereocenters in the cyclohexane ring of 3 sent for ECD calculations.  
 
Phomopsichromin D (4, C23H34O5, HRESIMS m/z 391.2473 [M + H]+ (calculated, 391.2440), 
[α]20D +0.2) was isolated as a white powder from the last and least lipophilic HPLC fraction of 
MPLC fraction D_C (Figure 2.2). 4 was notably distinct from 1-3 in that it was quite different in 
polarity (not soluble in CDCl3) and so all NMR data was obtained in DMSO-d6 (Table 2.4). The 
olefin region of the proton NMR spectrum of 4 was the most drastically different from 
compounds 1-3 and there was an additional phenol signal at δH 10.02, indicating that 4 lacked the 
completed chromene substructure. 
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Table 2.4. 1D and 2D data for phomopsichromin D (4) in DMSO-d6.  
Pos δCb δH (m, J(Hz))a HMBCc 
1 39.0 1.35 (m, 1 H) 2, 5, 6, 12, 14 
2 70.4 3.62 (q, 2.4, 1 H) 4, 6, 12 
3 34.1 1.4 (m, 1 H) 4 
  1.6 (m, 1 H) 4 
4 25.5 1.13 (m, 1 H) 1, 3, 5, 6, 14 
  1.53 (m, 1H)  
5 36.0 1.4 (m, 1 H) 4 
6 38.0   
7 36.0 1.17 (m, 1 H) 1, 5, 6, 8, 9, 14 
  1.23 (m, 1 H) 5, 6, 8, 9, 14 
8 32.4 1.69 (m, 1 H) 5, 15 
  1.75 (m, 1 H) 5, 10, 11, 15 
9 134.7   
10 121.8 5.12 (br t, 6.9, 1 H) 8, 11, 15, 16 
11 21.5 3.16 (br d, 7.2, 2 H) 7, 8, 9, 10, 15, 16, 17, 21 
12 12.7 0.84 (d, 7.2, 3 H) 1, 2, 6 
13 15.7 0.74 (d, 6.6, 3 H) 4 
14 17.3 0.75 (s, 3 H) 1, 6, 7 
15 16.1 1.70 (s, 3 H) 7, 8, 9, 10, 11, 16 
16 112.0   
17 159.6   
-OH  12.61 (s, 1 H) 16, 17, 18, 21 
18 103.6   
19 139.8   
20 110.4 6.23 (s, 1 H) 11, 16, 17, 18, 21, 22, 23 
21 162.8   
-OH  10.02 (s, 1 H) 16, 17, 20, 21 
22 23.8 2.38 (s, 3 H) 18, 19, 20, 21, 23 
23 174.1   
a 1H NMR recorded at 500 MHz, reported in ppm (multiplicity, J-coupling in Hz, integration); b 
13C NMR recorded at 125 MHz; c recorded from a gHMBCAD experiment at 500 MHz and 
reported as positions of carbons.   
 
2D NMR data (Figure 2.9) further supported this, and the “open” carbon skeleton was assigned 
and confirmed by comparison to literature data on known compound 6. Stereochemistry on the 
cyclohexane ring was set as in compounds 1-3. The double bond of the open chain was 
determined to be E based on the comparison of the J-value of H-10 to the literature. 
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Figure 2.9. Important COSY, HMBC, and NOE correlations in phomopsichromin D (4). 
 
Phomopsichromin E (5) was isolated as a white powder, C23H32O5; HRESIMS m/z 389.2363 [M 
+ H]+, [α]20D -0.4. By comparing 5 to 4 it was immediately evident that the only difference 
between the two was the increased oxidation at C-2. Comparison to 1 and 4, along with the 2D 
data for 5 (Table 2.5), completed the structure (Figure 2.10).  
 
 
Figure 2.10. Important COSY and HMBC correlations in phomopsichromin E (5). 
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Table 2.5. 1D and 2D data for phomopsichromin E (5) in DMSO-d6.  
Pos δCb δH (m, J(Hz))a HMBCc 
1 49.2 2.53 (q, 6.7, 1 H) 2, 5, 6, 12, 14 
2 212.6   
3 40.7 2.1 (m, 1 H) 1, 2, 4, 5 
  2.4 (m, 1 H)  
4 30.3 1.47 (m, 1 H) 3, 5, 13 
  1.76 (m, 1 H) 6 
5 35.0 1.99 (m, 1 H) 3, 4, 6, 13, 14  
6 42.7   
7 35.4 1.23 (m, 1 H) 5, 6, 8, 14 
  1.32 (m, 1 H) 1, 6, 8, 9, 14 
8 32.0 1.8 (m, 1 H) 7, 9, 10, 15 
  1.91 (m, 1 H) 7, 9, 10, 15 
9 134.2   
10 122.2 5.18 (br t, 6.8, 1 H) 8, 11, 15, 16 
11 21.5 3.17 (d, 7.1, 2 H) 9, 10, 16, 17, 21 
12 7.5 0.76 (d, 6.6, 3 H) 1, 2, 6, 7 
13 14.7 0.81 (d, 6.6, 3 H) 4, 5, 6, 12 
14 15.0 0.46 (s, 3 H) 1, 5, 6 
15 16.1 1.73 (s, 3 H) 8, 9, 10, 16 
16 111.9   
17 159.6   
-OH  12.62 (s, 1 H)  
18 103.6   
19 139.9   
20 110.4 6.23 (s, 1 H) 16, 17, 18, 22  
21 162.8   
-OH  10.04 (s, 1 H) 16, 17, 20, 21 
22 23.7 2.39 (s, 3 H) 18, 19, 20,  
23 174.1   
a 1H NMR recorded at 600 MHz, reported in ppm (multiplicity, J-coupling in Hz, integration); b 
13C NMR recorded at 200 MHz; c recorded from a gHMBCAD experiment at 600 MHz and 
reported as positions of carbons.   
 
2.4. Bioactivities 
Phomopsichromins A (1), B (2), C (3), and E (5) all show reasonable activity against the 
infected macrophage model of the Leishmania donovani parasite at 3, 1.9, 0.67, and 0.80 µM, 
respectively. Interestingly, neither phomopsichromin D (4) nor LL-Z1272ε (6) showed any 
activity towards the parasite or the macrophages.  
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Phomopsichromin C (3) was the only compound with any notable activity against any of 
the ESKAPE pathogens, with an MIC against MRSA of 58 µM. In a drug wash-out study, 3 was 
determined to be bactericidal. Impressively, this compound exhibits an MBC99 of 47 µM, which 
is reasonably close to the control gentamicin (20 µM in this assay). However, 3 also displays 
notable cytotoxicity towards HepG4 human liver cells, with an LD50 of 37 µM. Further 
supporting its cytotoxicity and lack of specificity, 3 is also active against the macrophage 
contained Leishmania donovani as mentioned above.  
1, 2, and 5 all displayed activity against MRSA at extremely high concentrations (> 500 
µM) and further cytotoxicity testing may be useful. If these compounds continue to be selective 
against the Leishmania donovani parasite, further biological testing against that, and other 
parasite targets would be warranted.  
While none of the phomopsichromins immediately emerge as promising lead compounds 
against ESKAPE or Leishmania donovani, with a group of compounds of this size, and 
interesting “natural structure activity relationship (SAR) study” is beginning to take form. It is 
notable that 4 remains inactive, despite being nothing more than the ring-open form of 2. 
Meanwhile, 1 and its ring opened form, 5, display similar bioactivities. While six compounds is 
hardly enough to constitute a true SAR study, one can imagine that with the isolation (or 
synthesis) of more of these analogs, a pharmacophore may well begin to emerge. A fungal 
source is ideal for such studies as more material of these, and any other discovered compounds, 
could be obtained quite easily and in high quantities.  
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2.5.  Future Directions  
 Our Phomopsis sp. isolate proved to be a producer of new, bioactive chemistry, and I 
believe, may still have biosynthetic potential remaining to be discovered. All six compounds 
discussed herein were isolated from the extract of the control growth condition. The extracts 
from the modified growth conditions remain to be explored. Additionally, NMR data suggests 
that there may be more phomopsichromins (or other known or new derivatives) as minor 
components of the investigated fractions that were abandoned due to time constraints. This strain 
remains archived in the Baker lab fungal library, along with the other 6 isolates from the branch 
piece. These organisms are all known to produce bioactive extracts and would all be interesting 
targets for further chemical analysis and growth culture optimization.  
This genera is known to have great biosynthetic potential and despite being such a well-
studied organism, environmental strains such as the one investigated here continue to be 
producers of new compounds. I believe that the work discussed herein stands as another layer of 
support for environmental microbial isolates as a promising source of new chemistry for drug 
discovery.  
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Chapter 3 
The Creation of a Large Fungal Isolate and Extract Library 
 
3.1. Curating a Fungal Library 
 The Baker lab is currently home to over 7000 microbial isolates. With a focus on 
filamentous fungi, this library includes micro-organisms isolated from marine and terrestrial 
environments in Florida and Antarctica. The isolation techniques employed to build this library 
have evolved over time, inspired by the work of colleagues, techniques found in the literature,1–3 
and the findings of various protocol optimization experiments. Isolation techniques vary 
according to source and isolate targets, but can be described by the following general protocol: 1) 
tissue surface sterilization with a 10% bleach solution and/or isopropyl alcohol; 2) tissue 
subsampling into 1 cm cross-sections; 3) plating in triplicate onto solid media plates of variable 
composition; 4) careful monitoring of colony growth on solid media plates for a period of 1-4 
weeks in the lab; and 5) transferring individual colonies to new isolation plates of similar 
composition. The last step is repeated until a pure colony is established for each isolate.   
Variations in solid media plate composition are employed to target a wide range of fungi 
and bacteria, and all tissue samples collected are plated across 6-10 different media types to 
access the microbial diversity that can be found living within each target organism.2 Each plate 
type is designed with the following general ingredients in varying concentrations: a nutrient 
source, agar, salt, and small molecule antibacterial and antifungal agents in sub-lethal doses to 
discourage the growth of fast-growing organisms. Available nutrient mixtures include: Sabaraud 
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Dextrose Broth (SDB), Potato Dextrose Broth (PDB), Tryptic Soy Broth (TSB), Malt Broth, 
Actino Agar, and glycerol. Small molecule additives include: nystatin, cycloheximide, and 
chloramphenicol. Solid media types are curated for each collection expedition based on source 
and microbial targets.  
Collection locations and source organisms represented in the isolate library are varied. 
Some examples of organisms commonly sampled for microbial isolation include: Floridian 
mangroves (Rhizophora mangle, Avicennia germinans, and Laguncularia racemose), mangrove 
associated trees (Conocarpus erectus, and Coccoloba uvifera), and benthic marine invertebrates 
including sponges, tunicates, and corals. Collection date, location, and source organism 
identification is all carefully recorded in field notebooks during each expedition.  
To accommodate different field conditions, two different collection techniques have been 
developed. The first technique is field plating, in which tissue samples are surface sterilized and 
directly plated on location onto solid media plates (“field plates”), which are then transferred 
back to the lab for monitoring of growth. The second technique is glycerol cryotube preservation, 
in which tissue samples are surface sterilized, frozen and stored for transit in a 20% glycerol 
solution in cryotubes before being plated in the lab. This allows for microbial collections to take 
place around the world, preserving tissues and micro-organisms until they can be processed in 
the lab. Table 3.1 illustrates collection details for all collection trips by the Baker lab between 
2011 and 2017.  
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Table 3.1. Collection details for collection trips from Fall 2011 to Spring 2017.  
Season, Year Location 
Target 
Source 
Organism(s) 
Target 
Micro-
Organism(s) 
Collection 
Technique 
Spring, 2012 Everglades National Park, FL MG F, B FP 
Summer, 2012 Keys Marine Lab, FL MG, MA F, B, A, M FP 
Summer,  
2011, 2013 
R.V. Bellows, Dry Tortugas 
National Park, FL 
MA F, B FP 
Fall, 2013 
Inter-coastal Islands, 
Dunedin, FL 
MG F FP 
Spring, 2014 
Tampa Bay, St. Petersburg, 
FL 
MG F FP 
Summer, 2014 Keys Marine Lab, FL MG, MA F FP 
Summer, 
2014-  
Fall, 2015 
Inter-coastal Islands, 
Dunedin, FL 
MG F, B L 
Summer, 2015 
R.V. Weatherbird, Gulf of 
Mexico 
MA F, B GC 
Spring 2016 Palmer Station, Antarctica MA F, B GC 
Fall 2016- 
Spring 2017 
R.V. Akademik Troyshnikov, 
ACE, Antarctica 
MA F, B GC 
Spring, 2017 Palmer Station, Antarctica MA F, B GC 
MG= mangrove and mangrove associate plant material; MA= benthic marine macro-organisms 
(ie, sponges, tunicates, corals); F= fungi; B= bacteria; A= actinobacteria; M=myxobacteria; FP= 
field plating; GC= glycerol cryotube preservation; L= whole tissue samples returned to lab (not 
frozen) to follow isolation protocol (utilized for sampling sites close to the lab). 
 
 After establishing a pure isolate, all micro-organisms are archived in a 20% glycerol 
solution at -80 °C. Bacterial cells are suspended in the solution, while fungal material is stored as 
small cubes of growth cut from SDA isolation plates. Isolates are identified according to the 
following nomenclature: “Collection Location, Year- Source Organism Number- Isolation Plate 
Type-Isolate Number”. In this way, isolates can easily be grouped and retrieved according to any 
one of the collection or isolation parameters. Nearly 75% of the existing fungal isolates in this 
library were subjected to an epigenetics based high throughput screening (HTS) project.  
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3.2. Screening Protocols, Accomplishments 
 In accordance with two NIH R21 grants (NIH AI103673 and AI103715) a high 
throughput, epigenetics based fungal screening program was designed. A culture miniaturization 
and modification protocol was developed to accommodate the use of 20mL scintillation vials and 
a brown rice media. The histone deacetylase (HDAC) inhibitor sodium butyrate, and the DNA 
methyltransferase (DNMT) inhibitor 5-azacytidine were employed at concentrations of 100µM 
for epigenetic modification.3 With a target of screening 500 organisms in 3 growth conditions 
(Control, HDACi, and DNMTi) each month for 12 months, goal-oriented timelines and protocols 
(Table 3.2) were developed and put in place. Screening was completed with full-time staffing by 
2 graduate and approximately 20 undergraduate students. Trainings and proper protocol 
regulations were employed to ensure uniformity in the extracts generated by the program. A full 
methodology for the culture, extraction and related procedures can be found in Appendix B. By 
implementing the developed protocols, a library of nearly 10,000 fungal extracts was produced 
over a time period of 18 months. At the height of productivity, 1,500 extracts were being 
produced and screened each month.  
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Table 3.2. Weekly sequence of events for continuous production of fungal isolates and extract 
libraries. 
Monday Tuesday Wednesday Thursday Friday 
 
□ Make rice media  ≥ 
4 boxes (400 vials) 
 
□ Make isolation 
plates (types A,B,D 
& TSA =1L; C & 
SDA ≥ 2L) 
 
□ Make 200mL x 3 
SDB for Eppendorf 
 
□ Make glycerol 
cryotubes 
 
□ fill eppendorfs 
(SDB, HDAC, 
DNMT) 
 
□ Wash vials 
 
□ Isolate/ describe/ 
archive fungi 
 
 
□ Harvest, start 
extraction of 21 
day old samples 
 
□ Inoculate rice 
≥ 4 boxes (400 
vials) 
 
□ Wash vials 
 
 
 
 
□ Decant 
extracts 
 
□ Dry extracts 
under air 
 
□ Weigh 
samples 
 
□ Pre-weigh 
vials 
 
□ Wash vials 
 
□ Isolate/ 
describe/ 
archive fungi  
 
 
□ Weigh 
extracts 
 
□ Solvate 
extracts in 
DMSO 
 
□ Create plate 
maps 
 
□ Wash vials 
 
□ Isolate/ 
describe/ 
archive fungi  
 
 
□ Get hit report, 
slant & 
organize hits 
 
□ Plate extracts 
for bioassay and 
storage (CDDI) 
 
□ Wash vials 
 
□ Isolate/ 
describe/ 
archive fungi  
 
 
 
  The resulting extract library was dispersed for screening and archived in DMSO at a 
concentration of 10mg/mL in 96-well plate format. Beyond the scope of the original two grant 
funded screening targets (the ESKAPE pathogens and Leishmania donovani), extracts have been 
distributed for screening in a number of additional targets, resulting in a body of data that can 
inform high level prioritization of active extracts. Additional screening is ongoing, but extract 
data to date includes bioactivities against the ESKAPE pathogens, Leishmania donovani, J774 
macrophage cells, Mycobacterium tuberculosis, Clostridium difficile, and Naegleria fowleri. The 
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library was additionally screened against a number of cell-based cancer targets and in a yeast 
based multiplex assay for anti-helminthics. Some active extracts were investigated by 
metabolomic analysis.  
 
3.3. Metabolomic Analysis  
 Extracts from a subset of organisms producing bioactivities were subjected to 
metabolomics analysis to investigate and confirm chemical diversity of the extract library and 
effectiveness of epigenetic modification techniques. Bioassay results showed desirable 
distribution of active extracts among the three culture conditions, and in each assay, organisms 
displaying activity only after modification accounted for 15-30% of all activity observed (Figure 
3.1).  
 
Figure 3.1. a) Representative pie chart from bioassay data, in this case, ESKAPE activity, that 
shows the activity boosting effects of the epigenetic modification; b) Representative pie chart 
from bioassay data, in this case, ESKAPE activity, that demonstrates distribution of activity 
across the three treatment conditions. This is the overall trend amongst all testing completed to 
date.  
  
To support and further investigate this diversity of activity, 123 extracts from 41 active 
organisms were analyzed via LC-QToF-MS. This subset of samples included active and non-
active extracts (for instance, in the case that an organism only displayed activity after 
Active
Organisms
Modified
Only
Total
Screened
Control
HDAC
DNMT
Total
Screened
a b 
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modification, the control extract was still included in the analysis). It included a wide range of 
isolates from different collections, isolation media, and source organisms. The LC-QToF-MS 
data were summarized into a list of ‘chemical entities’ (HRESIMS @ retention time) for each 
sample using Agilent Qualitative Analysis and Mass Profiler Professional software (full 
protocols in Appendix B). Each sample, identified by its list of chemical entities, could then be 
statistically compared using Multidimensional Scaling (MDS). Each sample was also identified 
by a number of additional factors, including biological activity, culture treatment, and isolate 
identity. Using Primer 6 software, MDS plots could be generated and annotated with any of these 
factors. This analysis allowed for a visual representation of the chemical similarity of the isolates 
and extracts to one another, and verified the chemical diversity of both the fungal library as well 
as the different culture treatments (Figure 3.2 and 3.3).  
 
Figure 3.2. An MDS plot of the Bray Curtis Similarity matrix of square root transformed data 
for 123 extracts (replicates averaged) from the screening program. Chemically unique samples 
(i.e. sample 93 in the top right quadrant) are clearly visible.  
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Figure 3.3. An MDS plot of the Bray Curtis Similarity matrix of square root transformed data 
for 9 randomly selected organisms from those represented in Figure 3.2. Each organism is 
denoted by an individual color, while each culture treatment is represented by a shape (control = 
triangle, HDAC = circle, DNMT = square). Full shapes represent extracts with ESKAPE activity, 
empty shapes represent no activity. Similarity contours highlight cluster analysis across 
organisms and treatments.   
 
In Figure 3.3 we can see that some organisms share less than 20% similarity with the other 
analyzed organisms (e.g. KML12-14MG-B2a). Additionally, we can see that for some 
organisms, different culture conditions induce an extract dissimilarity as high as 60% (e.g. 
EG10-47C-1). This data illustrates not only chemical uniqueness between different fungal 
isolates- validating our collection and isolation protocols- but also allows organisms in which the 
epigenetic modification has had a large impact on the metabolite profile to be identified. 
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Organisms whose modified extracts exhibit unique chemistry and biological activities would be 
of high interest for scale up and chemical analysis.  
Through the processing for MDS analysis, this data is also ideally prepared for 
dereplication efforts. With a robustly annotated database of known cytotoxins, nuisance 
compounds could be quickly identified and their extracts de-prioritized.  
This data represents an exercise in metabolomics analysis of a small subset of screened 
extracts, but could be scaled up and performed on the entire extract library for high-level analysis 
of all available chemistry.  
 
3.4. Training Set Results 
 Another subset of the extract library (1305 extracts, 13% of the total library) was 
screened fully against Mycobacterium tuberculosis (TB), the ESAKPE pathogens, Leishmania 
donovani, Naegleria fowleri, and the J774 murine macrophage cell line. Using stringent 
definitions of 'active' to moderate the hit rate, 16% of these 1305 extracts were determined to be 
active. While this number is quite large, this is a result of the fact that 77% of the hits were hits 
in only one assay. Within this subset, accounting for all bioactivities, the previously observed 
trends in each of the individual assays (Figure 3.1) were verified; the three culture treatments 
were equally effective in producing active extracts, and 39% of active fungi only produced hits 
in the HDACi and DNMTi culture conditions.  
To analyze this data in the most meaningful way, strict activity cut-offs were set for each 
bioassay. For simplicity, the ESKAPE pathogens’ MICs were reported as a single scaled score4 
for all 6 pathogens; an extract was considered ‘active’ in this assay if it had a scaled score ≥ 7. 
For highest clinical relevance, only extracts exhibiting an IC50 value < 1 μg mL-1 in the infected 
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macrophage model of the Leishmania donovani parasite were included.  TB activity was 
included when ≥ 85%, and activity against Naegleria fowleri was defined as inhibition of >33% 
at either concentration tested (50 and 5 µg/mL). Any cytotoxicity against the J774 macrophage 
cells up to 20 μg/mL was also included. Results can be seen in Figure 3.4. 
 
 
Figure 3.4. Selectivity of active extracts. 
 
Only 48 active extracts (23% of total active, 4% of total screened) were not specific to a single 
target organism. 17 extracts (8%, 1%) were active only against N. fowleri, 53 (25%, 4%) against 
the ESKAPE panel, 37 (17%, 3%) against Mycobacterium tuberculosis, 41 (20%, 3%) against 
the L. donovani infected macrophage, and 14 (7%, 1%) were cytotoxic only against the J774 
macrophages. When the definition of ‘active’ was relaxed in a secondary hit, (i.e. an extract was 
only considered ‘selective’ if it had reported activity only one of the 4 assays) 100 extracts, 48% 
of active extracts, retained their qualification as ‘selective’. 
Naeglaria Leish IM ESKAPE TB
J774 Non-Specific Non-Active
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This is a unique set of data featuring extracts of diverse fungal origin screened against a 
wide range of eukaryotic and prokaryotic disease causing organisms. The specificity of 
bioactivity in this data set suggests unique underlying chemical profiles and, gratifyingly, 
provides strong support to our screening program design. With this data, we have demonstrated 
that vigorous front-end investigation (multiple bioassays, metabolomic analyses, dereplication, 
etc.) of a library of extracts can inform scale-up prioritization in a highly effective way for the 
greatest chance of isolating new, bioactive natural products. Scale-up efforts are underway to 
further validate these methods.  
 
3.5. Future Directions 
 With such promising data from the extract library, scale-ups of bioactive fungi have 
commenced. A scale-up protocol was developed (Appendix B) and samples prioritized according 
to data available at the time. With the completed analysis of the training set, newly prioritized 
organisms have been identified and are available for chemical investigation in future. Extracts 
that feature specific, potent, and induced bioactivities can be scaled up and subjected to chemical 
analysis including new dereplication protocols as updated databases become available. With the 
plethora of front-end analysis that has been employed and presented here, organisms can now be 
chosen for chemical investigation with confidence in the chances of discovering new, bioactive 
secondary metabolites.  
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Chapter 4 
 A New Citreohybriddione Discovered Via Epigenetic Modification 
 
4.1.  Citreohybridones and Citreohybriddiones 
 The hybrid strain KO 0031 of Penicillium citreo-viride B. IFO 6200 and 4692 has been 
reported to be a prolific producer of meroterpenoid secondary metabolites.1 Many of these hybrid 
polyketide-terpenoids are known to be feeding deterrents against the crop pest Plutella 
xylostella.2–5 The previously reported citreohybridones and citreohybriddiones are two groups of 
these fungal natural products (Figure 4.1). Herein, the isolations of a new citreohybriddione 
(citreohybriddione D, 1) from an environmental Penicillium sp. fungus will be discussed. 
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Figure 4.1. Some of the previously reported citreohybridones, citreohybriddiones A-C, and the 
new citreohybriddione D (1).  
 
4.2. KML12-14MG-B2a isolation 
 A number of collection trips to the Keys Marine Lab, Long Key, FL have targeted 
mangrove endophytes. Traveling by canoe and using field plating techniques (as described in 
Appendix B) samples were collected from areas all around the facility targeting a broad range of 
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micro-organisms. The Keys Marine Lab is uniquely located with access to a wide variety of 
mangrove environments (Figure 4.2).   
Figure 4.2. Google Maps satellite view of collection areas around Keys Marine Lab, Long Key 
Florida. Location markers: Blue = Keys Marine Lab; Red = developed mangrove areas; Green = 
protected mangrove areas within Long Key State Park; Yellow = exposed mangrove areas; 
Purple = landfill mangrove areas. 
 
KML12-14MG-B2a is a Penicillium sp. isolated from the 2012 Keys Marine Lab trip. 
This organism was isolated from the stem tissue of a juvenile Rhizophora mangle tree in an 
exposed mangrove community on the west side of Long Key. This fungus was isolated on a solid 
water agar plate containing sub-lethal doses of both nystatin and cycloheximide. On SDA this 
organism has a typical Penicillium morphology, growing radially from the inoculated mycelia 
with a light green/ white color and fluffy sporulating bodies. 
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4.3. Initial Bioactivities, Scale-up, Epigenetic Modification, and Identification  
 Like most of the fungal isolates in the Baker Lab microbial library, KML12-14MG-B2a 
was cultured and screened as a part of the screening program introduced in Chapter 3. This 
isolate emerged early as an important hit against the ESKAPE pathogens, hitting against both 
gram positive and gram negative pathogens in the Control and HDACi growth conditions (Table 
4.1). In support of the design of the screening program, the HDACi culture produced a 
consistently active extract across replicate cultures, while repeated Control cultures produced 
inconsistent activity. Demonstrating the ability of these organisms to regulate their biosynthetic 
machinery and the effectiveness of the HDACi culture conditions, KML12-14MG-B2a became a 
model organism for scale-up and chemical investigation protocols.  
 
Table 4.1. Screening results for KML12-14MG-B2a.  
Sample Information MIC (µg/mL) 
Date Loc Extract ID 200 100 50 25 10 
1/9/2014 F1 KML12-14MG-B2a (HIT) CONTROL EKAP EKAP EKAP EAP EA 
1/9/2014 F2 KML12-14MG-B2a (HIT) HDAC EKAP EKAP - - - 
1/9/2014 F3 KML12-14MG-B2a (HIT) DNMT - - - - - 
2/3/2014 P2 D7 KML12-14MG-B2a (HIT) CONTROL - - - - - 
2/3/2014 P2 D8 KML12-14MG-B2a (HIT) HDAC ESKAP ESKAP ESKAP EKP EK 
2/3/2014 P2 D9 KML12-14MG-B2a (HIT) DNMT - - - - - 
This organism was screened multiple times as a part of a subset of isolates chosen to verify 
reproducibility in the screening protocol. Activity is indicated by the first letter of the pathogen 
the extract showed activity against. E = Enterococcus faecium, S = Staphylococcus aureus, K = 
Klebsiella pneumoniae, A = Acinetobacter baumannii, P = Pseudomonas aeruginosa. 
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 KML12-14MG-B2a was scaled up in control culture conditions on 700g of brown rice 
(autoclaved with 1.4L DI water) and inoculated in 100mL of SDB in 2 types of Unicorn brand 
mycobags and a 3L fernbach flask. After 21 days of incubation, both types of mycobag (Unicorn 
types 3T and 14A) were found to produce sterile, fully optimized growth (i.e. all rice material 
covered with growth) that resulted in extracts of similar mass. The fernbach flask culture proved 
significantly less desirable, with fungal growth only on the top of the solid rice due to an 
inability to agitate the culture throughout the culture process.  
Epigenetically modified cultures on KML12-14MG-B2a were then scaled up using the 
same protocols (at this time, Unicorn bag types 3T and 14A were used interchangeably 
according to supply. Type 3T bags were later purchased in bulk and all further scale-ups done in 
those bags). Again, resulting growth was uncontaminated and represented complete media 
coverage. The cultures each resulted in approximately 70g of crude extract after a 3 day 
exhaustive extraction (day 1: 50mL MeOH, 750 mL EtOAc; days 2 and 3: 800 mL EtOAc). 
Extracts were filtered over celite and sent for bioassay. Unfortunately, the crude extracts of the 
scale-ups did not replicate the activity seen in the small scale cultures. A liquid: liquid partition 
between EtOAc and H2O, followed by NP MPLC separation of the EtOAc partition was 
performed on each extract, and the resulting fractions sent for bioassay. Again, disappointingly, 
the fractions returned inactive. Scale-up optimization efforts were continued with other 
organisms in search of a scale up protocol that could be standardized and used in a scale-up 
screening program. Due to interesting NMR data, chemical investigation continued on the 
fractions of the HDACi extract of KML12-14MG-B2a.  
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 KML12-14MG-B2a was identified using sanger sequencing of the 18S ribosomal spacer 
region (Appendix C). Agreeing with the previously observed morphology, the isolate was 
identified to the genus level as a Penicillium sp.  
 
4.4.  Compound Isolation and Structure Elucidation 
 The MPLC separation of KML12-14MG-B2a HDACi resulted in 10 fraction (Figure 
4.3). With no bioactivity in any of the fractions, compound elucidation proceeded via NMR 
guided fractionation. NMR analysis of all 10 fractions identified fraction F as interesting for 
further investigation. HPLC separation of F was completed in normal phase (n-hexanes: ethyl 
acetate) on a silica column to yield 10 fractions (Figure 4.4). Fraction F-2 was discovered to 
contain the new meroterpenoid, citreohybriddione D (1).  
 
Figure 4.3. The NP MPLC chromatogram of KML12-14MG-B2a HDACi.  
 
 
 
A  B C D E F G H I J 
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Figure 4.4. The NP HPLC chromatogram of KML12-14MG-B2a HDACi- F.  
 
 Fraction F-2 was further purified on silica to yield compound 1. The 1H NMR spectrum 
of 1 was notable in that it contained 8 methyl signals (Table 4.2) and almost nothing in the olefin 
region. Investigation of the 13C data confirmed the presence of a large number of quaternary 
carbons, indicating a highly functionalized fused ring system such as a polyketide. The 
HRESIMS of 503.2640 [M + H]+ resembled the terpenoid skeletons of the citreohybridones and 
citreohybriddiones, but did not match any of the previously reported compounds. 13C NMR 
signals of carbons 1-12 strongly matched citreohybridone D, however carbons 13-18 more 
closely resembled citreohybriddione B.1  
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Table 4.2. 1D and 2D data for citreohybriddione D (1) in CDCl3.  
Pos δCb δH (m, J(Hz))a HMBCc 
1 27.8 1.03 (m, 1 H) 2, 9, 10, 22, 23, 25 
  2.38 (m, 1 H) 3, 5, 9, 10 
2 23.3 1.6 (m, 2 H) 10 
3 76.8 4.68 (t, 2.6, 1H) 1, 5, 26 
4 36.9   
5 47.7 1.83 (m, 1 H) 4, 6, 10, 23, 24  
6 16.9 1.8 (m, 1 H) 4, 8, 10 
  2.01 (m, 1 H) 7, 10 
7 30.8 2.83 (m, 1 H) 5, 6, 8, 22 
  2.38 (m, 1 H)  5, 9, 10 
8 38.6  8, 10, 11, 12, 23 
9 53.5 2.21 (m, 1 H)  
10 52.2   
11 126.4 5.85 (s, 1 H) 8, 9, 10, 13, 21 
12 133.0   
13 60.8   
14 70.4   
15 210.6   
16 72.1   
17 206.7   
18 19.8 1.4 (s, 3 H) 15, 16, 17 
19 167.3   
20 16.4 1.31 (s, 3 H) 12, 13, 14, 17 
21 18.8 1.7 (s, 3 H) 11, 12, 13 
22 19.5 1.17 (s, 3 H) 7, 8, 9, 14 
23 204.4 10.14 (s, 1 H) 1, 10, 22 
24 26.5 0.97 (s, 3 H) 2, 3, 4, 5, 25 
25 21.3 0.9 (s, 3 H) 3, 4, 5, 24 
3-OAc 170.6   
3- OAc 21.3 2.12 (s, 3 H) 26 
16- OH  2.16 (s, 1 H) 15, 16, 17 
19- OMe 52.0 3.63 (s, 3 H) 19 
a 1H NMR recorded at 500 MHz, reported in ppm (multiplicity, J-coupling in Hz, integration); b 
13C NMR recorded at 200 MHz; c recorded from a gHMBCAD experiment at 500 MHz and 
reported as positions of carbons.   
 
With conformation from 2D NMR experiments (Figure 4.5), it was determined that 1 is, in fact a 
new citreohybriddione lacking any lactone or epoxide ring structures. 2D NOESY data 
confirmed that the absolute stereochemistry matches what has been previously reported for 
similar compounds (Figure 4.6).1  
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Figure 4.5. Important COSY, HMBC, and NOESY correlations in Citreohybriddione D (1).  
 
NOE correlations between the methoxy at C-19 (δH 3.63) and the methyl groups at C-18 (δH 
1.40) and C-20 (δH 1.31) confirmed that the D-ring in 1 is up as in the other citreohybriddiones. 
The alcohol on C-16 of 1 has the same orientation as that in citreohybriddione B. Through-space 
correlations between C-22, 23, and 25 confirm that the stereochemistry of the A and B rings of 1 
are as reported in citreohybriddione A.  
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Figure 4.6. A 3D depiction of 1 for stereochemical review.  
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4.5. Future Directions 
 Citreohybriddione D (1) was isolated from the HDACi treatment extract. Initial 
investigation via HPLC of similar fractions indicated that 1 may have also been present in the 
DNMTi extract as well, but appeared absent in the control treatment fractions. However, 
HRESIMS investigation of the ethyl acetate partitions of all three treatment extracts revealed that 
1 could be found in all treatments. Nevertheless, HRESIMS and NMR analysis shows that there 
are notable chemical differences between the control and modified conditions, indicating that 
there may be many other new compounds to be found from this Penicillium sp. yet.  
 The culture optimization of KML12-14MG-B2a was not completed due to time restraints. 
This organism remains active in the small scale, and warrants further study to be able to replicate 
that activity on a culture scale that allows for chemical investigation of the active compound(s). 
The isolation of 1 confirms that this Penicillium sp. contains PKSs (polyketide synthases) that 
are capable of producing interesting secondary metabolites. Additionally, the small scale 
screening results confirm that this organism responds favorably to HDACi treatment, indicating 
that efforts in culture optimization would likely be rewarded with the production of many 
otherwise silenced natural products.  
 While there are no reported activities for any of the citreohybriddiones (including 1) 
against human disease, further testing of this new compound is warranted. Due to mass 
limitations, 1 was only screened against the ESKAPE pathogens and the Leishmania donovani 
parasite. Feeding studies and cytotoxicity profiling would be interesting to see how it compares 
to the rest of the compounds in this class.    
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Appendix A: Experimental and Supporting Data for Chapter 2 
 
 
Fungal Strain Identification  
MPLC Run Parameters and Chromatograms 
HPLC Run Parameters and Chromatograms 
Compound Data 
 
Fungal Strain Identification 
The fungal isolate “BB11-2” was sequenced using sanger sequencing of the 18S 
ribosomal spacer region. The forward and reverse primers used can be found in table A1. The 
PCR product was sent to europhins sequencing company which yielded the sequences that were 
blasted using NCBI nucleotide blast for sequence similarity. 
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Table A1. The forward and reverse primers used for the fungal strain identification of BB11-2. 
18S forward 
primers 
NNNNNNNNNNNNNTTGGTTTCTAGGACCGCCGTAATGATTAAT
AGGGACAGTCGGGGGCATCAGTATTCAATCGTCAGAG 
GTGAAATTCTTGGATCGATTGAAGACTAACTACTGCGAAAGCA
TTTGCCAAGGATGTTTTCATTAATCAGGAACGAAAGT 
TAGGGGATCGAAAACGATCAGATACCGTTGTAGTCTTAATCAT
AAACTATGCCCACTAGGGATCNGGCGGTGTTATTTCT 
18S reverse 
primers 
NNNNNNNNNNNNNNNCNGNTCNCCCCTTGTGGTGCCCTTCCGT
CAATTTCTTTAAGTTTCAGCCTTGCGACCATACTCCC 
CCCAGAACCCAAAAACTTTACTTTCGTGTAAGGTGCCGAGCGG
GTCAAGAAATAACACCGCCCGATCCCTAGTCGGCATA 
GTTTATGGTTAAGACTACAACGGTATCTGATCGTTTTCGATNCC
CTAACTTTCGTTCCTGATTNANGANAACATCCTTGG 
GAAATGCTTTCCNANTAATNNGNCTTCNATCAAATCCTCA 
 
 
Figure A1. NCBI nucleotide blast results for BB11-2 forward primers. 
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Figure A2. NCBI nucleotide blast results for BB11-2 reverse primers. 
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MPLC Run Parameters and Chromatograms 
 
 
Figure A3. NP MPLC chromatogram of BB11-2 Control EtOAc partition.  
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Figure A4. A second NP MPLC of BB11-2 Control fraction D from the first MPLC separation. 
Fraction C (bottles 4 & 5) contained the phomopsichromins.  
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Figure A5. NP MPLC chromatogram of BB11-2 HDACi EtOAc partition.  
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Figure A6. NP MPLC chromatogram of BB11-2_DNMTi EtOAc partition.  
 
HPLC Run Parameters and Chromatograms 
Normal phase HPLC separation was completed with a normal phase gradient of hexanes to ethyl 
acetate over 35 minutes on a semi-preperative Phenominex® Cyano column (5µm, 100Å, 250 x 
10mm) using UV and ELSD detection. Reverse phase HPLC separation was completed with a 
RP gradient of water to acetonitrile or methanol on a Phenominex® C18 column (5µm, 100Å, 
250x 4.6mm) using UV and ELSD detection.  
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Figure A7. NP HPLC chromatogram (black) and ELSD trace (blue) of BB11-2_D_C.  
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Compound Data 
Phomopsichromin A (1): C23H30O5; HRESIMS m/z 369.2034 [M + H – H2O]+ ( C23H29O4 
calculated, 369.2066), m/z 387.2137 [M + H]+ ( C23H31O5 calculated, 387.2171), m/z 409.1954 
[M + Na]+ (C23H30O5Na calculated, 409.1991); UV (MeOH) λmax (log ε) 250 (4.97) nm; [α]20D 
+1.2 (c 0.1, MeOH); IR (thin film) 3450, 2980, 2360, 1700, 1600, 1575, 1450, 1400, 1300, 1090 
cm-1; 1H NMR Data (500 MHz, CDCl3) δ ppm 0.59 (s, 3 H), 0.89 (d, J=6.8 Hz, 3 H), 0.91 (d, 
J=6.8 Hz, 3 H), 1.41 (m, 1 H), 1.44 (s, 3 H), 1.48 (m, 1 H), 1.52 (m, 1 H), 1.64 (m, 1 H), 1.77 
(m, 1 H), 1.85 (m, 1 H), 1.97 (m, 1 H), 2.33 (m, 1 H), 2.36 (m, 1 H), 2.41 (q, J=6.6 Hz, 1 H), 
2.55 (s, 3 H), 5.46 (d, J=10.2 Hz, 1 H), 6.24 (s, 1 H), 6.76 (d, J=10.2 Hz, 1 H), 11.74 (s, 1 H); 
13C NMR (125 MHz, CDCl3) δ ppm 7.5 (CH3, C-12), 14.9 (CH3, C-13), 15.4 (CH3, C-14), 30.6 
(CH2, C-7), 30.8 (CH2, C-4), 34.3 (CH2, C-8), 36.1 (CH, C-5), 41.5 (CH2, C-3), 43.2 (C-6), 50.4 
(CH, C-1), 79.8 (C-9), 103.6 (C-18), 106.8 (C-16), 111.9 (CH, C-20), 116.9 (CH, C-11), 125.8 
(CH, C-10), 144.4 (C-19), 158.6 (C-21), 160.6 (C-17), 175.1 (C-23) 213.8 (C-2). 
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Figure A8. 1H NMR Spectrum (500 MHz, CDCl3) of Phomopsichromin A (1).
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Figure A9. 13C NMR Spectrum (125 MHz, CDCl3) of Phomopsichromin A (1). 
F2 Chemical Shif t (ppm) 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
50
100
150
200
 
Figure A10. 1H-13C gHSQCAD NMR Spectrum (600 MHz, CDCl3) of Phomopsichromin A (1).  
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Figure A11. 1H-13C gHMBCAD NMR Spectrum (500 MHz, CDCl3) of Phomopsichromin A (1). 
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Figure A12. 1H-1H gCOSY NMR Spectrum (500 MHz, CDCl3) of Phomopsichromin A (1). 
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Figure A13. 1H-1H NOESY NMR Spectrum (600 MHz, CDCl3) of Phomopsichromin A (1). 
 
Phomopsichromin B (2):C23H32O5; HRMS m/z 371.2222 [M + H – H2O]+ ( C23H31O4 calculated, 
371.2222), m/z 389.2322 [M + H]+ (C23H33O5 calculated, 389.2328), m/z 411.2145 [M + Na]+ 
(C23H32O5Na calculated, 411.2147); UV (MeOH) λmax (log ε) 250 (4.08) nm; [α]20D -1.5 (c 0.1, 
MeOH); IR (thin film) 3450, 2930, 2380, 1675, 1625, 1600, 1575, 1460, 1400, 1300, 1090 cm-1; 
1H NMR Data (600 MHz, CDCl3) δ ppm 0.82 (d, J=6.6 Hz, 3 H), 0.86 (s, 3 H), 0.95 (d, J=7.1 
Hz, 3 H), 1.27 (m, 1 H), 1.35 (m, 2 H), 1.41 (s, 3 H), 1.43 (m, 1H), 1.45 (m, 1 H), 1.46 (m, 1H), 
1.55 (m, 1 H), 1.63 (m, 2 H), 1.8 (m, 1 H), 2.53 (s, 3 H), 3.85 (q, 2.8, 1 H), 5.46 (d, J=10.2 Hz, 1 
H), 6.22 (s, 1 H), 6.74 (d, J=10.2 Hz, 1 H), 11.80 (s, 1 H); 13C NMR (125 MHz, CDCl3) δ ppm 
12.3 (CH3, C-12), 15.6 (CH3, C-13), 17.3 (CH3, C-14), 24.4 (CH3, C-22), 25.4 (CH2, C-4), 27.0 
(CH3, C-15), 30.9 (CH2, C-7), 33.9 (CH2, C-3), 34.4 (CH2, C-8), 36.5 (CH, C-5), 38.2 (C-6), 
39.4 (CH, C-1), 73.1 (CH, C-2), 80.1 (C-9), 103.4 (C-18), 106.9 (C-16), 111.9 (CH, C-20), 116.6 
(CH, C-11), 126.2 (CH, C-10), 144.1 (C-19), 158.7 (C-21), 160.6 (C-17), 174.7 (C-23). 
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Figure A14. 1H NMR Spectrum (600 MHz, CDCl3) of Phomopsichromin B (2). 
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Figure A15. 13C NMR Spectrum (125 MHz, CDCl3) of Phomopsichromin B (2).
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Figure A16. 1H-13C gHSQCAD NMR Spectrum (600 MHz, CDCl3) of Phomopsichromin B (2). 
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Figure A17. 1H-13C gHMBCAD NMR Spectrum (500 MHz, CDCl3) of Phomopsichromin B (2). 
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Figure A18. 1H-1H gCOSY NMR Spectrum (600 MHz, CDCl3) of Phomopsichromin B (2). 
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Figure A19. 1H-1H NOESY NMR Spectrum (600 MHz, CDCl3) of Phomopsichromin B (2). 
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Figure A20. 1H NMR Spectrum (400 MHz, CDCl3) of methylated phomopsichromin B (7). A 
new methoxy signal can be seen at δH 3.92.  
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Figure A21. 13C NMR Spectrum (500 MHz, CHCl3) of methylated phomopsichromin B (7). 24 
13C signals can be seen. 
 
Phomopsichromin C (3): C25H34O6; HRESIMS m/z 413.2330 [M + H – H2O]+ (C25H33O5 
calculated, 413.2328), m/z 431.2434 [M + H]+ (C25H35O6 calculated, 431.2434), m/z 453.2256 
[M + Na]+ (C25H34O6Na calculated, 453.2253); UV (MeOH) λmax (log ε) 255 (4.21) nm; [α]20D 
+1.3 (c 0.1, MeOH); IR (thin film) 2930, 1740, 1675, 1600, 1580, 1400, 1300, 1350, 1090 cm-1; 
1H NMR Data (600 MHz, CDCl3) δ ppm 0.83 (2d, J=6.6 Hz, 6 H; s, 3 H), 1.29 (m, 1 H), 1.40 - 
1.43 (m, 6 H), 1.47 (m, 1 H), 1.5 (m, 2 H), 1.55 (m, 1 H), 1.65 (m, 1 H), 1.81 (m, 1 H), 2.05 (s, 3 
H), 2.53 (s, 3 H), 4.97 (q, 2.0, 1 H), 5.45 (d, J=10.2 Hz, 1 H), 6.22 (s, 1 H), 6.74 (d, J=10.0 Hz, 1 
H), 11.82 (s, 1 H); 13C NMR (125 MHz, CDCl3) δ ppm 12.0 (CH3, C-12), 15.6 (CH3, C-13), 16.7 
(CH3, C-14), 21.4 (CH3, C-25), 24.4 (CH3, C-22), 25.8 (CH2, C-4), 27.1 (CH3, C-15), 30.7 (CH2, 
C-7), 30.9 (CH2, C-3), 34.4 (CH2, C-8), 36.2 (CH, C-5), 38.3 (C, C-6), 38.5 (CH, C-1), 75.1 
83 
 
(CH, C-2), 80.1 (C, C-9), 103.3 (C, C-18), 106.8 (C, C-16), 111.9 (CH, C-20), 116.7 (CH, C-11), 
126.1 (CH, C-10), 144.1 (C, C-19), 158.7 (C, C-21), 160.6 (C, C-17), 170.8 (CO2CH3, C-24), 
174.4 (COOH, C-23). 
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Figure A22. 1H NMR Spectrum (600 MHz, CDCl3) of Phomopsichromin C (3). 
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Figure A23. 13C NMR Spectrum (125 MHz, CDCl3) of Phomopsichromin C (3). 
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Figure A24. 1H-13C gHSQCAD NMR Spectrum (600 MHz, CDCl3) of Phomopsichromin C (3). 
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Figure A25. 1H-13C gHMBCAD NMR Spectrum (500 MHz, CDCl3) of Phomopsichromin C (3). 
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Figure A26. 1H-1H gCOSY NMR Spectrum (600 MHz, CDCl3) of Phomopsichromin C (3). 
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Phomopsichromin D (4): C23H34O5; HRESIMS m/z 373.2373 [M + H – H2O]+ (C23H33O4 
calculated, 373.2379), m/z 391.2473 [M + H]+ (C23H35O5 calculated, 391.2484), m/z 413.2298 
[M + Na]+ (C23H34O5Na calculated, 413.2304); UV (MeOH) λmax (log ε) 225 (5.89) nm; [α]20D 
+0.2 (c 0.1, MeOH); IR (thin film) 3400, 2930, 1600, 1500, 1450, 1360, 1300, 1180, 1080 cm-1; 
1H NMR (500 MHz, DMSO-d6) δ ppm 0.74 (d, J=6.6 Hz, 3 H), 0.75 (s, 3 H), 0.84 (d, J=7.1 Hz, 
3 H), 1.13 (m, 1 H), 1.17 (m, 1 H), 1.23 (m, 1 H), 1.35 (m, 1 H), 1.4 (m, 2 H), 1.53 (m, 1H), 1.6 
(m, 1 H), 1.69 (m, 1 H), 1.70 (s, 3 H), 1.75 (m, 1 H), 2.38 (s, 3 H), 3.16 (br d, J=7.1 Hz, 2 H), 
3.62 (q, 2.4, 1 H), 5.12 (br t, J=6.9 Hz, 1 H), 6.23 (s, 1 H), 10.02 (s, 1 H), 12.61 (s, 1 H); 13C 
NMR (125 MHz, DMSO-d6) δ ppm 12.7 (CH3, C-12), 15.7 (CH3, C-13), 16.1 (CH3, C-15), 17.3 
(CH3, C-14), 21.5 (CH2, C-11), 23.8 (CH3, C-22), 25.5 (CH2, C-4), 32.4 (CH2, C-8), 34.1 (CH2, 
C-3), 36.0 (CH, C-5), 36.1 (CH, C-7), 38.0 (C, C-6), 39.0 (CH, C-1), 70.4 (CH, C-2), 103.6 (C, 
C-18), 110.4 (CH, C-20), 112.0 (C, C-16), 121.8 (CH, C-10), 134.7 (C, C-9), 139.8 (C, C-19), 
159.6 (C, C-17), 162.8 (C, C-21), 174.1 (C, C-23). 
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Figure A27. 1H NMR Spectrum (500 MHz, DMSO-d6) of Phomopsichromin D (4). 
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Figure A28. 13C NMR Spectrum (125 MHz, DMSO-d6) of Phomopsichromin D (4). 
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Figure A29. 1H-13C gHSQCAD NMR Spectrum (600 MHz, DMSO-d6) of Phomopsichromin D 
(4). 
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Figure A30. 1H-13C gHMBCAD NMR Spectrum (500 MHz, DMSO-d6) of Phomopsichromin D 
(4). 
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Figure A31. 1H-1H gCOSY NMR Spectrum (500 MHz, DMSO-d6) of Phomopsichromin D (4). 
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Phomopsichromin E (5): C23H32O5; HRESIMS m/z 371.2229 [M + H – H2O]+ (C23H31O4 
calculated 371.2222), 389.2363 [M + H]+ (C23H33O5 calculated 389.2328), 411.2152 [M + Na]+ 
(C23H32O5Na calculated 411.2147); UV (MeOH) λmax (log ε) 220 (4.14); [α]20D -0.4 (c 0.1, 
MeOH); IR (thin film) 3390, 2950, 1590, 1450, 1300, 1160, 1090, 1020 cm-1; 1H NMR Data 
(600 MHz, DMSO-d6) δ ppm 0.46 (s, 3 H), 0.76 (d, J=6.6 Hz, 3 H), 0.81 (d, J=6.6 Hz, 3 H), 1.23 
(m, 1 H), 1.32 (m, 1 H), 1.47 (m, 1 H), 1.73 (s, 3 H),  1.76 (m, 1 H), 1.80 (m, 1 H), 1.91 (m, 1 
H), 1.99 (s, 1 H), 2.10 (m, 1 H), 2.39 (s, 3 H), 2.40 (m, 1 H), 2.53 (q, J=6.7 Hz, 1 H), 3.17 (d, 
J=7.1 Hz, 2 H), 5.18 (br t, J=6.7 Hz, 1 H), 6.23 (s, 1 H), 10.04 (s, 1 H), 12.62 (s, 1 H); 13C NMR 
(125 MHz, DMSO-d6) δ ppm 7.5 (CH3, C-12), 14.7 (CH3, C-13), 15.0 (CH3, C-14), 16.1 (CH3, C-
15), 21.5 (CH2, C-11), 23.7 (CH3, C-22),  30.3 (CH2, C-4), 32.0 (CH2, C-8), 35.0 (CH, C-5), 35.4 
(CH2, C-7), 40.7 (CH2, C-3), 42.7 (C, C-6), 49.2 (CH, C-1), 103.6 (C, C-18), 110.4 (CH, C-20), 
111.9 (C, C-16), 122.2 (CH, C-10), 134.2 (C, C-9), 139.9 (C, C-19), 159.6 (C, C-17), 162.8 (C, 
C-21), 174.1 (COOH, C-23), 212.6 (C, C-2). 
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Figure A32. 1H NMR Spectrum (600 MHz, DMSO-d6) of Phomopsichromin E (5). 
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Figure A33. 13C NMR Spectrum (201 MHz, DMSO-d6) of Phomopsichromin E (5). 
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Figure A34. 1H-13C gHSQCAD NMR Spectrum (600 MHz, DMSO-d6) of Phomopsichromin E 
(5). 
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Figure A35. 1H-13C gHMBCAD NMR Spectrum (600 MHz, DMSO-d6) of Phomopsichromin E 
(5). 
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Figure A36. 1H-1H gCOSY NMR Spectrum (600 MHz, DMSO-d6) of Phomopsichromin E (5). 
 
LL-Z1272ε (6): C23H32O4; HRESIMS m/z 373.2411 [M + H]+ (C23H33O4 calculated 373.2334); 
UV (MeOH) λmax (log ε) 224 (4.03) nm; IR (thin film) 3400, 2950, 2360, 1600, 1460, 1380, 
1300, 1080 cm-1; 1H NMR Data (600 MHz, CDCl3) δ ppm 0.59 (s, 3 H), 0.89 (d, J=6.6 Hz, 3 H), 
0.92 (d, J=6.6 Hz, 3 H), 1.39 (m, 1 H), 1.45 (m, 1 H), 1.62 (m, 1 H), 1.85 (m, 1H), 1.85 (s, 3 H), 
95 
 
1.91 (m, 1 H), 2.00 (m, 1 H), 2.06 (m, 1 H), 2.34 (m, 1 H), 2.35 (m, 1 H), 2.47 (q, J=6.5 Hz, 1 
H), 2.51 (s, 3 H), 3.41 (d, J=7.1 Hz, 2 H), 5.29 (br t, J=6.6 Hz, 1 H), 6.12 (br s, 1 H), 6.23 (s, 1 
H), 10.09 (s, 1 H), 12.76 (s, 1 H); 13C NMR (125 MHz, CDCl3) δ ppm 7.5 (CH3, C-12), 15.0 
(CH3, C-13), 15.3 (CH3, C-14), 16.5 (CH3, C-15), 18.0 (CH3, C-22), 21.2 (CH2, C-11), 30.9 
(CH2, C-4), 32.6 (CH2, C-8), 35.6 (CH2, C-7), 36.1 (CH, C-5), 41.5 (CH2, C-3), 43.4 (C-6), 50.4 
(CH, C-1), 110.6 (CH, C-20), 111.5 (C-16), 113.2 (C-18), 121.1 (CH, C-10), 139.2 (C-9), 142.0 
(C-19), 162.1 (C-21), 163.5 (C-17), 193.0 (CH, C-23), 213.9 (C-2). 
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Figure A37. 1H NMR Spectrum (600 MHz, CDCl3) of LL-Z1272ε (6). 
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Figure A38. 13C NMR Spectrum (125 MHz, CDCl3) of LL-Z1272ε (6). 
 
Table A2. Pure compound bioactivities of 1-6. 
Pure Compound Bioactivities 
Compound MRSA  
IC50 (µM) 
L. donovani 
IC50 (µM) 
Other 
1 518 3  
2 515 1.9  
3 58 0.67 
MRSA MBC99: 47 µM 
HepG4 LD50: 37 µM 
4 NA NA  
5 515 0.80  
6 NA 13  
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Appendix B: Experimental and Supporting Data for Ch. 3 
 
Microbial Isolation Protocols 
Screening Protocols 
LC-QToF-MS Protocols 
Metabolomic and Statistical Analysis Protocols 
Scale-up Protocols  
 
Microbial Isolation Protocols 
Nutrient media components (SDB, PDB, TSA, Actinomycete Isolation Agar, Malt Extract Agar) 
and agar were produced by BD™ Difco™ and purchased through Fisher Scientific. Glycerol, 
nystatin, cycloheximide, and chloramphenicol were purchased from Sigma Aldrich®.  
Solid media was mixed, heated, and autoclaved according to manufacturer’s instructions and 
poured to set in Fisherbrand™ petri dishes.  
After collections, field plates were incubated at 20-25°C (room temperature), 4°C (refrigerated), 
or 26-30°C (heated) as source organism or microbial targets dictated. Generally, bacterial plates 
were heated and fungal plates were left at room temperature for collections in warm climates. 
Cold water microbial isolation generally took place with refrigeration. Field plates were 
incubated for 1-4 weeks, and disposed of after all colonies were isolated and/or after the whole 
plate was covered in microbial growth. 
Isolated pure colonies were grown on SDA (fungi) and TSA (bacteria) for archiving as described 
above. Descriptions of each organism on this standard media were recorded.  
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Screening Protocols 
Each fungal isolate was grown on SDA from either glycerol stocks or isolation plates, and after a 
colony was established, was subsampled for screening. 1cm cubes of fungal material and agar 
were inoculated in triplicate into 3 sterile Eppendorf™ tubes containing 1.25mL each: SDB 
(control), 100 µM sodium butyrate in SDB (HDACi), and 100µM 5-aza-cytidine in SDB 
(DNMTi). Sodium butyrate and 5-aza-cytidine were purchased from Sigma Aldrich®. The 
SDB/modifier/ fungal mixture was agitated, and then each poured over 1g rice media in a 
Fisherbrand™ 20mL glass scintillation vial. Rice media was made by autoclaving 1g (1/4 tsp) of 
brown rice with 4mL DI water. Once inoculated, rice vials were incubated at 28°C for 21 days.  
After 21 days, all contaminated/ non-growing culture sets were removed. Cultures were spritzed 
with ~500µL distilled MeOH. The fungal rice cake was broken apart with a clean spatula. 10mL 
distilled EtOAc was added using a glass 10mL pipette and allow to extract overnight on bench 
top. Extracts were carefully decanted into clean, pre-weighed scintillation vials after 24 hours.  
Extracts were dried under air for 24 hours, resuspended in DMSO at a concentration of 
10mg/mL, and plated in 96-well format on a TECAN Freedom EVO 150 liquid handling 
automated workstation. Five replicate Corning™ clear polystyrene 96-well microplates were 
prepared with 150µL of extracts/ well for bioassay. Remaining extract material was stored in 
duplicate Fisherbrand™ 96-well DeepWell™ polypropylene microplates. All extract plates were 
stored at -20°C.  
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LC-QToF-MS Protocols 
Extracts were dried of DMSO and suspended in MeOH at a concentration of 0.1mg/mL. The 
resulting solution was filtered over 0.2µm Phenomenex® RC syringe filters and were injected in 
triplicate on the LC-QToF-MS for analysis.  
Analysis was completed on an Agilent 6540 LC/QTOF with Agilent Jet-stream Electrospray 
Ionization. A Kinetex C18 (5µm, 100 Å, 2.1mm ID, 50mm length) column was used with the 
following instrument parameters:  
Acquisition Method Report    
TOF/Q-TOF Mass Spectrometer Parameters: 
Component Name   MS Q-TOF  
Component Model  G6540A 
Tune File    Autotune.tun 
MS Abs. threshold   200  
MS Rel. threshold (%)  0.010 
Can wait for temp.   Enable  
Fast Polarity    N/A 
Ion Source    Dual AJS ESI  
Stop Time (min)   No Limit/As Pump 
Storage Mode   Both 
Ion Mode   Dual AJS ESI 
Acquisition Mode MS1:  
Scan Rate (spectra/sec)  5.46 
Max Range (m/z)   1000 
Min Range (m/z)   50 
Source Parameters:  
Sheath Gas Flow   8 
Sheath Gas Temp   300 
Nebulizer (psig)   40 
Gas Flow (l/min)   10 
Gas Temp (°C)   300 
Ion Polarity   Positive 
Scan Source Parameters: 
Octopole RF Peak   750 
Skimmer1    65 
Fragmentor    125 
Nozzle Voltage (V)   1000 
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VCap     3500 
Chrom Type: TIC; Label: TIC; Offset: 15; Y-Range: 10000000 
Auto Recalibration: 
Min Height (counts)  1000 
Detection Window (ppm)  100 
Average Scans   1 
Reference Masses: 
Ref Nebulizer (psig)   0 
Use Bottle A Ref Nebulizer  True 
Ref Mass Enabled   Enabled 
Reference Masses: 
<Positive> 
922.00979800 
121.05087300 
HiP Sampler Parameters: 
Component Name   HiP Samplet 
Component Model  G1367E 
Draw Speed   100µL/min 
Eject Speed   100µL/min 
Draw Position Offset  0.0 mm 
Wait Time After Drawing 0.0 s 
Sample Flush Out Factor 5.0 
Vial/Well bottom sensing Yes 
Injection Mode  Injection with needle wash 
Injection Volume  10.0µL/min 
Needle Wash Location Flush Port 
Wash Time   5.0 s 
Automatic Delay Vol Red No 
Enable Overlap. Inj.  No 
Valve Switching  No 
Stop Time   As pump/ No limit 
Post Time Mode  Off 
Pump Parameters: 
Component Name   Binary Pump 
Component Model  G1312B 
Flow    0.600 mL/min 
Use Solvent Types  Yes 
Low Pressure Limit  0.00 bar 
High Pressure Limit  600.00 bar 
Maximum Flow Gradient 100.000 mL/min2 
Auto Stroke Calc. A  Yes 
Auto Stroke Calc. B  Yes 
Compressibility A  50 10e-6/bar 
Compressibility B  115 10e-6/bar 
Stoptime   9.00 min 
Posttime   1.00 min 
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Timetable  
 Time Function Parameter 
1 0.00 min Change Flow Flow 0.6 mL/min 
2 0.00 min Change Solvent Composition Solvent Composition A: 75.0 % B:25.0 % 
3 0.50 min Change Solvent Composition Solvent Composition A: 75.0 % B:25.0 % 
4 3.00 min Change Solvent Composition Solvent Composition A: 5.0 % B:95.0 % 
5 7.00 min Change Solvent Composition Solvent Composition A: 5.0 % B:95.0 % 
6 8.00 min Change Solvent Composition Solvent Composition A: 75.0 % B:25.0 % 
7 9.00 min Change Flow Flow 0.6 mL/min 
8 9.00 min Change Solvent Composition Solvent Composition A: 75.0 % B:25.0 % 
Solvent Composition 
 Channel Solvent 1 Name 1 Used Percent 
1 A H2O H2O+0.1% Formic Acid Yes 75.0 % 
2 B ACN ACN+0.1% Formic Acid Yes 25.0 % 
Column Comp. Parameters: 
Component Name   Column Comp 
Component Model  G1316A 
Left Temperature Control: 
Temperature Control Mode Temperature Set 
Temperature    35.00 °C 
Enable Analys. Left Temp No 
Right Temperature Control: 
Right Temp Cont Mode Combined 
Enable Analys. Right Temp No 
Stoptime mode  As pump/injector 
Posttime mode  Off 
 
 
 
 
Metabolomic and Statistical Analysis Protocols 
 Each sample for metabolomics analysis was prepared as above and run in triplicate 
according to the run parameters above. Resulting chromatograms were subjected to processing 
by Agilent MassHunter Qualitative Analysis. First, a list of compounds was generated using the 
Find By Molecular Feature tool. A peak height cutoff was set at 100 counts and results were 
limited to the largest 5000 compounds. Results were exported to .cef files that were transferred 
to Agilent Mass Profiler Professional (MPP). In MPP replicates were averaged and blanks were 
subtracted. The resulting table of samples and chemical entities (mass @ retention time) was 
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exported via Microsoft Excel and opened in Primer 6 for statistical analysis (Clarke, K. R.; 
Gorley, R. N. 2006. PRIMER v6: User Manual/Tutorial. Primer-E, Plymouth). Abundances were 
square root normalized and factors such as culture conditions and bioactivities were added to 
each sample identity. A Bray-Curtis similarity matrix was constructed from which cluster 
(dendogram) and multidimensional scaling (MDS) plots could be created.  
 
Scale-up Protocols 
A scale-up protocol that mirrored the screening culture protocol was developed. The optimized 
procedure was enacted for all scale-up level screening. Rice media was prepared in a Type 3T 
Unicorn bag according to the following procedure: 300g of brown rice was mixed with 500mL 
DI water and a heat sealer was used to seal the bag. Rice was autoclaved on a liquid cycle for 30 
minutes at 121°C. Each hit organism chosen for scale-up was grown on SDA from either 
glycerol stocks or isolation plates, and after a colony was established, was subsampled for 
screening. 1cm cubes of fungal material and agar were inoculated in triplicate into 3 sterile 50 
mL Falcon™ tubes containing 50mL each: SDB (control), 100 µM sodium butyrate in SDB 
(HDACi), and 100µM 5-aza-cytidine in SDB (DNMTi). Rice bags were cut open in a sterile 
environment, the fungal/ liquid media mixture poured in, and resealed. Rice was agitated once a 
week for a 21 day culture period. Extraction was completed by spritzing the culture with distilled 
MeOH to dampen the spores, transferring the material to a large beaker, and extracting overnight 
in a 1:3 MeOH: EtoAc mixture, followed by two 24-hour extractions in EtOAc. Extracts were 
collected, filtered, and dried down for chemical analysis.  
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Appendix C: Experimental and Supporting Data for Ch. 4 
 
Fungal Strain Identification  
MPLC Run Parameters and Chromatograms 
HPLC Run Parameters and Chromatograms 
Compound Data 
 
 
Fungal Strain Identification  
The fungal isolate KML12-14MG-B2a was sequenced using sanger sequencing of the 18S 
ribosomal spacer region. The resulting sequences were blasted using NCBI nucleotide blast for 
sequence similarity.  
 
 
Figure C1. NCBI nucleotide blast results for KML12-14MG-B2a forward primers. 
 
 
Figure C2. NCBI nucleotide blast results for KML12-14MG-B2a reverse primers. 
 
104 
 
 
MPLC Run Parameters and Chromatograms 
 
 
Figure C3. NP MPLC chromatogram of KML12-14MG-B2a_HDAC EtOAc partition. Control 
and DNMT EtOAc partitions were run with the same parameters.  
 
 
HPLC Run Parameters and Chromatograms 
Normal phase HPLC separation was completed with a normal phase gradient of hexanes to ethyl 
acetate over 35 minutes on a semi-preperative Phenominex® Luna Silica (2) column (5µm, 
100Å, 250 x 10mm) using UV and ELSD detection.  
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Figure C4. NP HPLC ELSD trace of KML12-14MG-B2a_Control_D. This fraction from MPLC 
was most similar in elution time to fraction KML12-14MG-B2a_HDAC_F and was used for 
comparison.  
 
Figure C5. NP HPLC ELSD trace KML12-14MG-B2a_HDAC_F. Citreohybriddione D was 
isolated from the most abundant peak, fraction 2. 
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Figure C6. NP HPLC ELSD trace of KML12-14MG-B2a_DNMT_C. This fraction from MPLC 
was most similar in elution time to fraction KML12-14MG-B2a_HDAC_F and was used for 
comparison. 
 
 
Compound Data  
Citreohybriddione D (1): C28H38O8; HRESIMS m/z 443.2431 [M - OAc]+ (C26H35O6 calculated, 
443.2434), 503.2640 [M + H]+ (C28H39O8 calculated, 503.2645), 525.2465 [M + Na]+ 
(C28H38O8Na calculated, 525.2464); [α]20D + 0.4 (c 0.1, MeOH); 1H NMR Data (500 MHz, 
CDCl3) δ ppm 0.90 (s, 3 H), 0.97 (s, 3 H), 1.03 (m, 1 H), 1.17 (s, 3 H), 1.31 (s, 3 H), 1.40 (s, 3 
H), 1.68 (m, 1 H), 1.70 (m, 3 H), 1.80 (m, 1 H), 1.83 (m, 1 H), 2.01 (m, 1 H), 2.12 (s, 3 H), 2.16 
(s, 1 H), 2.21 (m, 1 H), 2.38 (m, 1 H), 2.83 (m, 1 H), 3.63 (s, 3 H), 4.68 (t, J=2.6 Hz, 1 H), 5.85 
(s, 1 H), 10.14 (s, 1 H); 13C NMR (200 MHz, CDCl3) δ ppm 16.4 (CH3, C-20), 16.9 (CH2, C-6), 
18.8 (CH3, C-21), 19.5 (CH3, C-22), 19.8 (CH3, C-18), 21.3 (CH3, C-25), 21.3 (CH3, C-27), 23.3 
(CH2, C-2), 26.5 (CH3, C-24), 27.8 (CH2, C-1), 30.8 (CH2, C-7), 36.9 (C, C-4), 38.6 (C, C-8), 
47.7 (CH, C-5), 52.0 (CH3, C-28), 52.2 (C, C-10), 53.5 (CH, C-9), 60.8 (C, C-13), 70.4 (C, C-
14), 72.1 (C, C-16), 76.8 (CH, C-3), 133.0 (C, C-12), 126.4 (CH, C-11), 167.3 (C, C-19), 170.6 
(C, C-26), 204.4 (CH, C-23), 206.7 (C, C-17), 210.6 (C, C-15).   
107 
 
KML12-14MG-B2a_HDAC_F2-1f_dd500_PROTON_01.esp
Chemical Shif t (ppm)11 10 9 8 7 6 5 4 3 2
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
90
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
0.
97
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
17
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
31
1.
311
.4
0
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
40
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
55
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
1.
70
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
01
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
02
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
12
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
16
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
2.
38
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
3.
63
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
67
4.
674
.6
8
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
68
4.
685
.8
5
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
85
5.
851
0.
14
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
10
.1
4
 
Figure C7. 1H NMR Spectrum (500 MHz, CDCl3) of citreohybriddione D. 
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Figure C8. C13 NMR Spectrum (200 MHz, CDCl3) of citreohybriddione D. 
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Figure C9. 1H-13C  gHSQCAD NMR Spectrum (800 MHz, CDCl3) of citreohybriddione D. 
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Figure C10. 1H-13C gHMBCAD NMR Spectrum (500 MHz, CDCl3) of citreohybriddione D. 
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Figure C11. 1H-1H gCOSY NMR Spectrum (600 MHz, CDCl3) of citreohybriddione D. 
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Figure C12. 1H-1H NOESY NMR Spectrum (800 MHz, CDCl3) of citreohybriddione D. 
 
 
 
 
 
 
 
 
 
 
 
